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Abstract 
     Activated immune cells secrete proinflammatory cytokines that induce a generalized 
sickness response.  The following experiments were designed to determine whether the 
proinflammatory cytokine IL-1β is the peripheral mediator of sickness-induced cognitive 
dysfunction, as well as to characterize the cognitive processes that are disrupted during 
illness.   The effects of peripherally-administered IL-1β and LPS, an endotoxin that 
induces a peripheral immune response, are compared across learning and memory tasks, 
and on hippocampal LTP.  LPS impaired memory consolidation and inhibited EPSP 
expression, whereas IL-1β had no effects across tasks, nor on LTP expression.  However, 
IL-1β plus IL-6, inhibited hippocampal cell proliferation.  Therefore, sickness-induced 
cognitive dysfunction is characterized by a disruption of memory consolidation and an 
inhibition in hippocampal LTP.  In addition, whereas peripheral IL-1β, alone, is 
insufficient to disrupt learning and memory or hippocampal physiology, it may work with 
other proinflammatory cytokines, such as IL-6, to produce effects in the CNS. 
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     The first clue that peripheral cytokines could trigger cognitive dysfunction came from 
clinical observations of patients who had received cytokine therapy for cancer.  Adams 
and colleagues (1984) observed these patients to exhibit mild to moderate cognitive 
dysfunction after having received daily treatment with the proinflammatory cytokine, 
interferon-alpha.  Clear conclusions from these clinical observations concerning direct 
effects on cognition, however, could not be drawn because personality and mood changes 
were also observed.  Clinicians could not be certain as to whether the repertoire of 
behavioural changes they observed in their patients were results of the cytokine therapy 
they had received or the cancer itself.  Additional support for cytokine-induced cognitive 
dysfunction would come from behavioural observations of sick non-human animals. 
Sickness behaviour in non-human animals 
     Hart and colleagues (1988) were the first to characterize a set of behavioural changes 
common to both sick animals and people.  According to Hart et al. (1988), the most 
commonly recognized behavioral patterns of animals and people at the onset of febrile 
infectious diseases were lethargy, depression, anorexia, and reduction in grooming.  
Additional testing of laboratory animals suggested that sickness also induced anhedonia, 
or the lack of an ability to experience pleasure, hyperalgesia (i.e., enhanced 
responsiveness to pain), and cognitive dysfunction.  These animals resembled in many 
ways the patients who had undergone cytokine therapy in treatment for their cancer, as 
initially described by Adams et al. (1984).   However, rather than characterizing their 
behavioural observations as representing nothing more than debilitating side-effects of 
sickness, Hart and colleagues described their observations as a host of non-specific 
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 behavioural changes accompanying illness that were fundamentally adaptive.  That is, 
they theorized that, by re-routing bodily resources away from activities not necessary for 
immediate survival, the animal, or host, was able to provide more resources to mount the 
fever necessary to clear the body of infection (1988). Indeed, a few years later, Kluger 
described the febrile response as an adaptive homeostatic state that is characterized by an 
elevated set point in body temperature regulation (1992).   Hart et al. (1988) significantly 
advanced the idea that sickness behaviour was a coordinated and adaptive central 
response to this elevated set point.   
Sickness behaviour and the proinflammatory cytokines 
     Despite Hart et al.’s (1988) characterization of sickness behaviour and the earlier 
clinical suspicions that cytokines were responsible for causing it, no data were available 
to support a direct link between cytokines and the sickness response.  The support came 
in 1992 when Kent and colleagues reported that laboratory rats who were injected with 
bacterial endotoxins or proinflammatory cytokines displayed several behavioural signs of 
sickness, such as depressed locomotor activity, decreased exploration of their physical 
and social environments, and reduced food and water intake (Kent, Bluthé, Kelly, & 
Dantzer, 1992).  Their observations were sufficient to conclude that it was this peripheral 
release of the pro-inflammatory cytokines following immune activation that caused 
sickness behaviour. 
     The conclusion that a peripheral immune response could cause behavioural changes 
begot the question, then, of how the proinflammatory cytokines- molecules too large to 
directly cross the blood-brain barrier- gained access to the central nervous system (CNS).  
Though some proinflammatory cytokines can directly cross the blood-brain barrier 
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 (Konsman, 2000), several studies indicate that the central response to peripheral immune 
activation is largely due to brain-produced cytokines, whose production and activation 
are induced by peripheral pro-inflammatory signaling.  
      The peripheral proinflammatory cytokines can indirectly produce brain cytokines 
through both humoral and nervous system pathways.  The humoral route involves the 
activation of prostaglandins by peripheral proinflammatory cytokines. This signaling of 
prostaglandin production occurs at areas where the blood-brain barrier is either weak or 
absent, such as at the circumventricular organs.  Prostaglandins diffuse into the brain 
parenchyma where they initiate a signaling cascade that culminates in the brain’s own 
production of proinflammatory cytokines (Saper & Breder, 1994; Herkenhaum, Lee, & 
Baker, 1998; Laflamme & Rivest, 1999; Konsman, 2000). 
     The primary nerve responsible for transmitting peripheral proinflammatory- induced 
signals is the vagus nerve (Bluthé et al., 1994; Brady; Lynn, Herkenham, & Gottesfeld, 
1994;  Ericsson, Kovacs, & Sawchenko, 1994; Watkins et al., 1994; Ninjima, 1996; 
Gaykema et al., 1998;  Goehler, Gaykema, Hammack, Maier, & Watkins, 1998; 
Konsman, Luheshi, Bluthé, & Dantzer, 2000).  Peripherally activated immune cells 
induce the release of proinflammatory cytokines, which then activate vagal nerve fibers.  
This peripheral activation of the vagus nerve is transmitted to the point at which the 
vagus nerve terminates in the brain stem, the nucleus tractus solitarius (NTS).  
Glutamatergic projections from the NTS then sensitize different brain regions to the 
actions of brain-produced cytokines.  Current opinion holds that it is the synergistic 
activation of both these humoral and nervous system pathways that is responsible for the 
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 coordinated central response to peripheral immune activation (Konsman, Luheshi, 
Bluthé, & Dantzer, 2000; Dantzer, 2001). 
Interleukin-1 beta (IL-1β) 
IL-1β and Sickness Behaviour 
     As an understanding began to develop of how peripheral immune activation could 
cause behavioural changes, researchers began to focus on which, if any, of the 
proinflammatory cytokines was primarily responsible for inducing such changes.  
Because interleukin-1 beta (IL-1β) was observed to be one of the more potent 
proinflammatory cytokines and IL-1β receptors were located widely throughout the 
hypothalamus and hippocampus- brain structures largely responsible for orchestrating 
changes in mood and cognition- IL-1β became the focus of the majority of empirical 
investigation. 
     Indeed, growing investigation into cytokine-induced sickness behaviour supported the 
idea of IL-1β as the primary signaling molecule for sickness behaviour.  For example, it 
was observed that peripheral IL-1β administration inhibited both social interaction 
(Bluthe, Dantzer, & Kelley, 1992; Luheshi et al., 2000) and induced anorexia (Kent, 
Bret-Dibat, Kelley, & Dantzer, 1996) in rats.  From these promising studies, researchers 
began to look at IL-1β as the possible mediator of other sickness behaviours. 
IL-1β and Cognitive Dysfunction 
     Cognitive dysfunction, though less explored than the other sickness behaviours, is also 
currently held to be induced by peripheral and central IL-1β.  Cognitive processes in the 
rodent are investigated both behaviourally and physiologically.  At  the behavioural level, 
cognitive processes are often investigated using learning and memory tasks thought to 
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 depend upon the cerebral cortex, most often the hippocampus. Examples of such tasks 
include the Morris water task (Morris, 1981) or the contextual fear conditioning (CFC) 
task.  In the Morris water task, animals must learn to find a submerged platform in an 
opaque circular pool through the use of extra-pool cues.  In the contextual fear 
conditioning task, rather than maintaining a contextual representation of environmental 
cues to navigate through space, animals are tested on their ability to mount an appropriate 
fear response to a context in which they had previously received a foot shock.  Animals 
who display learned fear, evidenced by the amount of freezing they display in the original 
context in which they had received the shock, have acquired and maintained an 
association between contextual cues and shock.  Animals who receive central injections 
of  
 IL-1β are impaired in both tasks (Oitzl et al., 1993; Barrientos et al., 2002), suggesting 
that IL-1β acts centrally to disrupt hippocampal learning and memory systems. 
     Investigation into how IL-1β acts to disrupt hippocampal functioning has led to studies 
of IL-1β effects on hippocampal long-term potentiation (LTP).  LTP, a phenomenon 
initially described by Bliss and Lomo (1973), is an experimental manipulation by which 
high-frequency stimulation of a pre-synaptic neuron(s) causes an enhanced and long-
lasting (i.e., hours to days) post-synaptic response.  Because the enhanced post-synaptic 
response is only observed at synapses that have been artificially stimulated, LTP is held 
to tap the same or some of the same physiological processes that underlie normal 
learning.  It is hypothesized by many that learning is the behavioural result of the 
physiological enhancement of synaptic efficacy based upon an experience-dependent 
LTP-like process. 
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      Some evidence exists to suggest that IL-1β inhibits hippocampal LTP.  In vitro, the 
administration of IL-1β either inhibits or completely blocks the induction of LTP in the 
CA1 (Bellinger, Madamba, & Siggins, 1993), CA3 (Katsuki et al., 1990), and dentate 
gyrus (Cunningham, Murray, O’Neill, Lynch, & O’Connor, 1996) regions of the 
hippocampus.  In vivo studies on the anesthetized animal, show that the central 
administration of IL-1β inhibits LTP in the dentate gyrus (Murray & Lynch, 1998; 
Vereker, O’Donnell, & Lynch, 2000).  Such observations have led researchers to 
hypothesize that the proinflammatory cytokine IL-1β most likely disrupts hippocampal 
learning and memory through a disruption of hippocampal LTP. 
     Hippocampal neurogenesis, like hippocampal LTP, is a cellular process that could 
contribute to sickness-induced cognitive dysfunction .  Not only has hippocampal 
neurogenesis been observed to be up-or-down- regulated following different experiences 
(Kempermann, 2002, (review)), but hippocampal neurogenesis has also been functionally 
linked to a specific cognitive process, namely memory consolidation (Feng et al., 2001).  
It is plausible, therefore, that the experience of being sick with a bacterial infection 
disrupts hippocampal neurogenesis, and that this disruption contributes to hippocampal 
learning and memory impairments.  In fact, the peripheral immune activation has been 
demonstrated to inhibit hippocampal neurogenesis (Monje, Toda, & Palmer, 2003); 
however, no experiments investigating the effects of the peripheral administration of IL-
1β on hippocampal neurogenesis have been conducted.  In summary, very recent 
investigation into the effects of the peripheral immune response on hippocampal 
neurogenesis support an inhibitory effect of the immune response on hippocampal 
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 neurogenesis; however, no data are available to support whether peripheral IL-1β 
similarly inhibits this process. 
Summary 
Current Theory 
     To summarize, current theory holds that cognitive dysfunction represents an integral 
component of sickness behaviour.  Similar to other sickness behaviours, such as anorexia 
and social withdrawal, cognitive dysfunction is held to be induced by the 
proinflammatory cytokines that are released by immune cells during a peripheral immune 
response to an infectious agent.  Moreover, the pro-inflammatory cytokine, IL-1β, is held 
to be the primary peripheral and central signaling molecule of sickness-induced cognitive 
dysfunction (Danzer, 2001; Maier, 2003; Maier & Watkins, 2003).  The current theory 
holds that, through humoral and nervous system pathways, the peripheral release of IL-1β 
induces brain IL-1β production.  It is this brain production of IL-1β, in response to 
peripheral signaling by IL-1β, that then acts, at least in part, on hippocampal circuitry to 
disrupt learning and memory and its proposed physiological counterpart, LTP. 
     It is often the hope that a new theory of a biomedical process will lead to a new and 
improved medical treatment.  Following the initial discovery linking proinflammatory 
cytokines to sickness behaviour, including sickness-induced cognitive dysfunction, the 
proinflammatory cytokines have been linked to the neurological impairments common to, 
not only to acute infection, but also to HIV infection (Wesselingh & Thompson, 2001 
(review)); chronic pathological conditions, such as systemic lupus erythematosus ((SLE) 
Lauwerys & Houssiau, 2003 (review)); and the cognitive impairments that accompany 
aging (Wilson, Finch, & Cohen, 2002 (review)).  Furthermore, several researchers have 
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 supported anti-proinflammatory cytokine therapy for the treatment of inflammatory 
conditions.  For example, interleukin-6 has been identified as a therapeutic target in the 
treatment of both systemic-onset juvenile arthritis (Yokota, 2003 (review)) and Crohn’s 
disease (Ito, 2003 (review)).  Anti-cytokine therapies have also been proposed for 
inflammatory bowel disease (Ogata & Hibi, 2003 (review)) and heart disease (Diwan, 
Tran, Misra, & Mann, 2003 (review)).  It is conceivable, therefore, that anti-cytokine 
therapies can be developed to treat, not only sickness-induced cognitive dysfunction, but 
also the cognitive impairments that accompany other conditions that have an 
inflammation component (HIV infection, SLE, aging).  The growing focus on the 
proinflammatory cytokine, IL-1β, as the primary signaling molecule of sickness-induced 
cognitive dysfunction has made it a most attractive target for the cognitive dysfunction 
that accompanies these other conditions.  However, to successfully treat medical 
conditions, the correct targets for intervention need to be identified.  Despite the 
prominent role played by peripheral IL-1β in theory, available data currently provide 
insufficient evidence to narrowing the identification of peripheral IL-1β as a sole target 
for the pharmacological treatment of cognitive dysfunction.   
Weaknesses of Current Theory 
      The primary weakness of the current theory is whether or not the proinflammatory 
cytokine, IL-1β is, indeed, the primary signaling molecule of cognitive dysfunction.  
Certainly, this appears to hold true for brain IL-1β, as the central administration of IL-1β 
impairs performance in a variety of learning and memory tasks, including the Morris 
Water task (Oitzl et al., 1993) and the contextual fear conditioning task ((Barrientos et 
al., 2002); data reviewed in the Introduction to Experiments 3-7), but whether or not IL-
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 1β is the major signaling molecule in the periphery is less clear.  The majority of 
empirical investigation into IL-1β effects on learning and memory has described learning 
and memory deficits following central IL-1β administration.  Only one has published 
study has observed an inhibitory effect of peripheral IL-1β on performance in a 
hippocampal-dependent learning and memory task.  In 1995, Gibertini and colleagues 
observed that peripheral administration of IL-1β produced performance deficits in the 
Morris water task.  However, these deficits were later observed to disappear when the 
animals were subjected to different doses or training protocols (Gibertini, 1998), 
suggesting that the effects of peripheral IL-1β on learning and memory vary across dose 
and task conditions. More experiments, using a variety of tasks and doses, need to be 
done to determine the role of peripheral IL-1β in sickness-induced cognitive dysfunction.    
     Also, unlike global sickness behaviours, such as anorexia and reduced general motor 
activity, the measurement of cognition demands attention to its components.  That is, 
several different aspects of learning and memory can be measured.  For example, the 
learning or acquisition of a new task or a new set of cues can be dissociated from other 
cognitive processes, such as the short -or long-term retention of the task or cues.  Few 
researchers have dissociated these processes in their investigations, and, as a result, it is 
unclear if sickness-induced cognitive dysfunction is the manifestation of a global 
impairment in cognition, or if it is a process-specific disruption.  Moreover, cognitive 
impairments need to be dissociated,- through the use of appropriate motivational, 
perceptual, and sensori-motor controls,- from other non-cognitive effects that can impair 
learning and memory.   
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       A final weakness of the current theory involves whether or not an IL-1β-induced 
disruption of hippocampal LTP underlies the learning and memory impairments observed 
in IL-1β-treated animals.  The entirety of the investigation into IL-1β effects on 
hippocampal LTP has been in vitro or using in vivo anesthetized preparations.  Both 
methods involve acute tissue damage, which is well-recognized to induce 
proinflammatory cytokine expression (Jankowsky, Derrick, & Patterson, 2000).  Because 
both methods invoke a large-scale inflammatory response that complicates the 
interpretation of IL-1β effects on LTP, it is necessary to investigate the effects of 
proinflammatory cytokines on hippocampal LTP in an animal whose body has had 
sufficient time to recover from surgical-induced inflammation. 
     To summarize, then, available data only weakly support the current theory that the 
peripheral release of IL-1β by activated peripheral immune cells triggers the cognitive 
dysfunction component of sickness behaviour.  Data from behavioural studies only 
weakly support the theory, namely, because not enough data has been collected on the 
learning and memory response to peripheral IL-1β administration.  Because of the 
confounding effects of the preparations used to investigate the phenomenon, the available 
data also do not fully support hippocampal LTP disruption as a mechanim that underlies 
sickness-induced cognitive dysfunction.  Furthermore, no experiments have been done to 
determine whether the peripheral administration of IL-1β inhibits hippocampal LTP in a 
freely-moving animal.  Similarly, no experiments have been conducted to determine if 
the peripheral administration of IL-1β inhibits hippocampal neurogenesis, another 
cellular process empirically linked to learning and memory.  Finally, the majority of 
investigators have failed to separately assess different cognitive processes in their 
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 learning and memory protocols, and therefore, sickness-induced cognitive dysfunction 
has not been well-characterized.  
Research Questions 
     The primary question that inspired the following set of experiments is:  Is there a 
primary peripheral signaling role for the proinflammatory cytokine IL-1β in sickness-
induced cognitive dysfunction?  That is, will the peripheral administration of IL-1β, 
alone, be sufficient to trigger the sequence of events leading to disruption of learning and 
memory?  Further, will hippocampal LTP prove sensitive to the peripheral inflammatory 
response and, if so, will it also be sensitive to the peripheral administration of IL-1β?  
Finally, what specific cognitive process is disrupted in sickness behaviour; is it a global 
impairment or a process-specific (i.e., acquisition, consolidation, retention) disruption? 
     In order to separately characterize the physiological and behavioural effects of a full 
peripheral inflammatory response from those that are induced by only peripheral IL-1β, 
effects of IL-1β are compared to effects rendered by the bacterial endotoxin, 
lipopolysaccharide (LPS).  LPS is the cell wall (i.e. active component) of all gram-
negative bacteria and induces a full peripheral immune response common to infection, 
including the release of several bioactive mediators, such as oxygen free-radicals, 
prostaglandins, platelet-activating factor, and several proinflammatory cytokines 
(Rietschei & Brede, 1992).  Of the proinflammatory cytokines that are released in 
response to peripheral LPS administration, significant rises in plasma tumor necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6), in addition to IL-1β, have been observed 
(Rietschei & Brede, 1992; Kakizaki, Watanobe, Kohsaka, & Suda, 1999). 
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      Because it is well-known that both peripheral LPS and peripheral IL-1β are capable of 
triggering changes within the CNS through previously described humoral  (Saper & 
Breder, 1994; Herkenhaum et al., 1998; Laflamme & Rivest, 1999; Konsman, 2000).and 
neural mechanisms (Bluthé et al., 1994; Brady et al., 1994;  Ericsson et al., 1994; 
Watkins et al., 1994; Ninjima, 1996; Gaykema et al., 1998;  Goehler, et al., 1998; 
Konsman et al., 2000), indication of a centrally-mediated (i.e., feeding, fever, etc.) 
behavioural change following peripheral LPS and / or IL-1β adminstration is evidence 
that the peripherally-administered compound effectively signaled the central nervous 
system.  If LPS and IL-1β are administered at doses that have been previously 
demonstrated to cause central effects, and LPS, but not IL-1β, induces changes in 
learning, memory, or in hippocampal physiology, then it can reasonably be inferred that 
peripheral IL-1β is not the primary signaling molecule of sickness-induced cognitive 
dysfunction.  If this is the case, then other components of the peripheral immune 
response, such as TNF-α and IL-6, either working alone or synergistically with IL-1β, are 
responsible for sickness-induced cognitive dysfunction. 
     In the first set of experiments (Experiments 1-2), the effects of LPS are measured on:  
temperature, food consumption, body weight, and general motor activity.  If the 
peripheral administration of LPS induces a full peripheral immune response, then it 
should induce changes across all of these measures.  If LPS does induce a full peripheral 
inflammatory response, indicated by measurable signs of sickness, then effects of 
peripheral LPS and peripheral IL-1β on learning, memory, and hippocampal physiology 
can be compared.  This comparison is necessary to the investigation of whether cognitive 
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 dysfunction and disruption of hippocampal physiology constitute central components of 
sickness behaviour. 
     The second set of experiments (Experiments 3-7) is designed to test learning and 
memory across a variety of paradigms and doses to determine whether specific cognitive 
process(es) are sensitive to LPS and / or IL-1β.  Again, if LPS administration causes 
changes in learning and memory that are not evident following systemic IL-1β 
administration, then other components of the peripheral immune response that act alone 
or in concert with IL-1β are primarily responsible for sickness-induced cognitive 
dysfunction. 
     The third set of experiments (Experiments 8-9) are designed to test whether 
hippocampal LTP in the freely-moving animal is sensitive to the peripheral immune 
response and, if so, whether the systemic administration of IL-1β is sufficient to disrupt 
its expression.  A LPS or IL-1β-induced disruption of hippocampal LTP would support 
the theory of a mechanistic role for hippocampal LTP disruption in sickness-induced 
cognitive dysfunction, while the comparison of LPS- and IL-1β-induced effects will 
determine whether IL-1β is the primary peripheral signaling molecule of hippocampal 
LTP disruption. 
     The final experiment (Experiment 10) is designed to test the effects of the peripheral 
administration of IL-1β and IL-6 on hippocampal cell proliferation.  Though not a direct 
assessment of hippocampal neurogenesis, the quantification of hippocampal cell 
proliferation following peripheral proinflammatory cytokine administration should 
indicate whether the acute administration of proinflammatory cytokines, such as IL-1β 
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 and IL-6, exert inhibitory effects on a different (i.e., other than hippocampal LTP) 
hippocampal cellular process that correlates with learning and memory. 
     These experiments will answer the question of whether peripheral IL-1β is sufficient 
to trigger cognitive dysfunction and / or the disruption of hippocampal cellular processes.  
Furthermore, the experiments will attempt to characterize the learning and memory 
processes (i.e., acquisition, consolidation, retention) and underlying cellular processes 
(hippocampal LTP, hippocampal cell proliferation) that are disrupted in sickness-induced 
cognitive dysfunction.   
General Animals and Housing 
     Male adult Long-Evans rats, supplied by Charles Rivers Laboratories (Montreal, 
Quebec) were used in all experiments.  Rats were housed in pairs (individually housed in 
Experiments 8,9) and maintained on a constant light and dark schedule (light on 07:30 – 
19:30) in the animal housing facilities at the Canadian Centre for Behavioural 
Neuroscience at the University of Lethbridge.  Animals were allowed free access to both 
food and water throughout the experiments.  Blood samples taken from sentinel animals 
at the termination of each experiment verified that the vivarium room was free from 
bacteria/viruses/parasites which could induce peripheral immune activation in the rats 
and obscure effects of the experimental treatments.  All serology reports verified the 
vivarium room to be free from such organisms. 
Sickness Behaviour (Experiments 1-2) 
Introduction 
     Lipopolysaccharide (LPS), a potent endotoxin derived from gram-negative bacteria, 
should induce a full peripheral immune response in the rat (Rietschei & Brede, 1992; 
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 Kakizaki et al., 1999).  If sickness behaviour, described as a constellation of symptoms 
that accompanies illness (Hart, 1988), is a consistent behavioural phenomenon that 
accompanies infection, then several behavioural changes should occur in LPS-treated 
animals.  Indeed, LPS-treated animals have been observed to show reduced social 
exploration and weight loss (Bluthé, Dantzer, & Kelly, 1992; Swiergiel, Smagin, 
Johnson, & Dunn, 1997), as well as anhedonia (Borowski, Kokkinidis, Merali, & 
Anisman, 1998).  In addition, the systemic administration of an IL-1β antagonist blocks 
some behavioural signs of sickness, including loss of body weight and social withdrawal 
(Bluthé et al., 1992), implying that signaling by IL-1β is necessary to the induction of 
some components of the sickness response.  
     Prior to comparing the effects of peripheral LPS and IL-1β on cognition, it is 
necessary to confirm findings from previous studies that the peripheral administration of 
LPS does induce several sickness behaviours, such as decreased food intake and 
anhedonia (Bluthé et al., 1992; Swiergiel et al., 1997; Borowski, et al., 1998).  
Furthermore, it is necessary to confirm that LPS, at the same dose, produces a reliable 
inhibition of general motor activity. If it does, then it can be concluded that LPS induces 
a sufficient peripheral immune response,- effects of which can then be compared to those 
induced by IL-1β.  In Experiment 1, the effects of LPS on food consumption and weight 
are measured.  In Experiment 2, the effects of LPS on general motor activity are assessed.  
If LPS does reliably induce sickness behaviour, then reductions should be observed 
across all three measures.  
     Both experiments compare the effects of peripheral LPS to effects induced by 
peripheral IL-1β in order to establish a basis on which further comparisons of LPS and 
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 IL-1β effects on cognition can be compared.  An absence of an effect of peripheral IL-1β 
on cognition would signify an absence of an effect specifically on cognition, and not an 
inability of the compound to induce a central response. 
 
Methods 
Drugs  For Experiments 1 and 2, LPS was supplied by Sigma Aldrich (LPS Ecoli 026:B6; 
Sigma, Lot no. 101K4080; 3 million endotoxin units per MG) and IL-1β was supplied  by 
Research Diagnostics Inc.((RDI) catalog no. RDI-201b). Each compound was prepared in 
a pyrogen-free saline solution (Abbot Laboratories, Lot no. 79-613-DM-01) the morning 
of the experiment.  A pyrogen is any substance capable of producing a fever.  Therefore, 
in order not to obscure immune activation induced by the experimental treatment with 
saline-induced immune activation, pyrogen-free saline was used in all experiments.  
Procedure:  Experiment 1  Nine animals, divided equally into three groups (LPS, IL-1β, 
saline) were used in the first experiment to investigate the effects of LPS and IL-1β on 
food consumption and weight loss.  Baseline measurements for both food consumption 
and weight were taken for two days prior to injections.  Food consumption was measured 
by weighing the amount of food remaining in each animal’s cage at the same time each 
morning. 
     Injections were administered after two days of baseline measurements.  Animals 
received i.p. injections of:  100 μg/kg of LPS, 12μg/kg of IL-1β, or an equivalent volume 
of pyrogen-free saline.  The dose of LPS was chosen based on a previous study 
demonstrating an anhedonic-inducing effect of LPS at a similar dose (Borowski, 
Kokkinidis, Merali, & Anisman, 1998).  The dose of IL-1β was chosen based upon a 
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 preliminary experiment showing an inhibitory trend in hippocampal LTP at this dose (see 
Appendix C).  Presumably, these doses are sufficient to induce at least some central 
changes.  If sickness behaviour is a robust response to systemic infection, the same dose 
should also cause a robust sickness response evidenced across several behavioural 
measures. 
     Post-injections measurements of both food and weight were taken 24 hours following 
injections. 
Procedure:  Experiment 2  10 animals were used in Experiment 2 (LPS- 4, IL-1β-6) to 
test the effect of peripheral LPS and IL-1β administration on activity.  General motor 
activity was measured using activity-monitoring boxes ( 36 cm X  36 cm wire-mesh 
cages; manufactured in-house) individually equipped with infra-red sensors.  Activity 
was measured in one-hour intervals.  A 24-hour baseline measurement was taken in 
which the animals were allowed sufficient time to become familiar with their 
surroundings prior to injection. 
     On injection day, animals received injections of: 100 μg/kg of LPS, 12 μg/kg of IL-1β, 
or an equivalent volume of saline.  Animals were returned to their cages immediately 
following injections and left for the remainder of the experiment (24 hours). 
     General activity was measured as the total number of cage crosses detected for each 
animal.  Because the general activity monitoring system will often detect small 
movements by the animal and label them as crosses to the left or the right of the cage, 
these movements were not included in the analyses.  Rather, the outcome measurement 
was the average difference in the total number of cage crosses for each animal between 
the 24 hour post-injection period and the 24 hour baseline period. 
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      In addition to food consumption, weight, and general activity measurement, three 
three-hour measurements of brain temperature were recorded in an animal injected with:  
250 μg/kg of LPS,  25 μg/kg of  IL-1β, or an equivalent volume of pyrogen-free saline 
(see Appendix A).  Though lower doses (2 μg/kg) have been observed to induce a febrile 
response (Yirmiya, Tio, & Taylor, 1996), these does have been demonstrated to induce a 
robust febrile response that dissipates after 24 hours (Konsman, Luheshi, Bluthé, & 
Dantzer, 2000). 
Results 
Experiment 1  There was a significant difference between  saline and LPS- treated 
animals in both post-injection food consumption and body weight.  LPS-treated animals 
ate significantly less ((t (4) = -3.9, p <.05); see Figure 1) and weighed significantly less 
((t (4) = 3.7, p < .05; see Figure 2) than the saline-treated animals.  Baseline food 
consumption did not differ between groups (t (4) = -.42, p > .05), with both groups 
leaving approximately the same amount of food in their trays (LPS M = 234 g, saline M 
= 234 g). 
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Figure 1.  Effects of LPS on food consumption.  Mean and SEM of the amount of food remaining (g) at baseline and following 
injections of 100 μg/kg of LPS and an equi-volume amount of pyrogen-free saline.  *Significant difference in amount of food 
remaining 24 hours following injections (p < .05). 
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Figure 2.  Change in weight 24 hours following LPS injection.  Mean and SEM of change in weight (g) are depicted for animals 
injected with either 100 μg/kg of LPS or an equi-volume amount of pyrogen-free saline.  *Significant difference between groups 
in amount of weight gained or lost over the 24 hour period following injections  (p < .05). 
 
     As depicted in Figures 3 and 4, the peripheral administration of IL-1β also caused 
significant reductions in both food consumption (t (4) = -2.9, p < .05) and weight (t (4) = 
5.3, p < .05).  Though randomly assigned, a significant difference was also observed in 
baseline food consumption between treatment groups, with animals assigned to the IL-1β 
condition having eaten significantly more prior to injection than the animals who had 
been assigned to the saline condition (t (4) = 4.8, p < .01). 
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Figure 3.  Effects of  IL-1β on food consumption.  Mean and SEM of the amount of food remaining (g) at baseline and    
   following injections of 12 μg/kg of IL-1β and an equi-volume amount of pyrogen-free saline.  *Significant difference in  
   amounts of food remaining at baseline (p < .01) and 24 hours following injections (p <. 05). 
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Figure 4.  Change in weight 24 hours following IL-1β injection.  Mean and SEM of the change in weight (g) are depicted for animals 
injected with either 12 μg/kg of IL-1β  or an equi-volume amount of pyrogen-free saline.  *Significant difference between groups in 
amount of weight gained or lost over the 24 hour period following injections (p < .01). 
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Experiment 2   As depicted in Figure 5, LPS-treated animals were less active than saline-
treated animals (t (3) = -3.8, p < .05).  Whereas the LPS-treated animals averaged 
approximately 30 fewer crosses following injections, saline-treated animals averaged 50 
more crosses following injections. 
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Figure 5.  LPS effects on general  motor activity.  Mean and SEM are depicted of the difference in the total number of cage crosses 
before and after injections of either 100 μg / kg LPS or an equi-volume amount of pyrogen-free saline.  *Significant difference 
observed in difference in total number of crosses between LPS and saline-treated animals (p < .05). 
 
     No significant differences in 24-hour general motor activity were observed in animals 
treated with IL-1β compared to saline-treated animals (t (5) = .47, p > .05).  However, a 
closer look revealed a significant difference in general motor activity during the first 
eight hours following injection.  Though treatment groups did not differ during the first 
eight hours of baseline activity (t (5) = -.35, p > .05), the groups did differ in general 
activity during the first eight hours following injection, with IL-1β-treated animals 
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 averaging a significantly lower total number of crosses (( t (5) = 3.14,  p < .05; see Figure 
6). 
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Figure 6.  IL-1β effects on general motor activity during the first 8 hours following injection.  Mean and SEM are depicted  of the total 
number of crosses before and after injection with either 12μg/kg of  IL-1β or an equi-volume amount of pyrogen-free saline. 
*Significant difference observed between groups in general activity level in first 8 hours following injection (p < .05). 
 
     In addition to reductions observed in food consumption, weight, and general activity 
in both LPS and IL-1β-treated animals, brain temperature was elevated by both 
compounds (see Appendix A). 
Conclusions:  Experiments 1 & 2 
     Anorexia and fatigue are hallmark symptoms of infection.  These symptoms are 
components of a centrally-organized adaptive response, coined sickness behaviour, that is 
employed by the host to conserve the additional energy it requires to mount the febrile 
response necessary to effective pathogen clearance (Hart, 1988; Kluger, 1992).   
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      As observed in Experiments 1 and 2, the administration of LPS caused significant 
reductions in food consumption, weight, and in general motor activity.  It can reasonably 
be inferred that these behavioural changes were fundamental to the animal’s ability to 
mount the febrile response that was observed following the administration of endotoxin 
(Appendix A).   
     Not surprisingly, the effects of peripherally-administered IL-1β on food consumption 
and weight closely mirrored those rendered by LPS, as previous researchers have 
suggested a primary peripheral signaling role for IL-1β in these behaviours (Bluthé et al., 
1992; Kent et al., 1996).  In addition, though other proinflammatory cytokines, such as 
interleukin-6 (IL-6) and tumor necrosis factor- alpha (TNF-α) act centrally on the 
hypothalamus to induce the febrile response to infection, peripheral IL-1β appears to be 
the primary signaling molecule for this central febrile response to infection (Luheshi & 
Rothwell, 1996).    
     Interestingly, peripherally-administered IL-1β produces similar, but not identical 
effects to LPS on behavior.  This observation was most evident in Experiment 2, where 
LPS induced a general reduction in activity over a 24-hour interval, whereas IL-1β-
induced reductions were only observed during the first eight hours following injection, 
suggesting that the magnitude of the suppressive effect of IL-1β and LPS on general 
motor activity is different.  Indeed, other sickness behaviours, such as reduced food 
intake, which have been demonstrated to be induced by the peripheral administration of 
IL-1β (Bluthé et al., 1992; Kent et al., 1996), are attenuated, but not completely blocked 
by an IL-1β receptor antagonist (IL-1ra) following LPS adminstration.  This lack of an 
ability of an IL-1ra to completely block LPS-induced sickness behaviours, suggests that 
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 additional immune molecules and / or inflammatory events are involved in some sickness 
behaviours.  Certainly, the observation of differential effects of LPS and IL-1β on general 
motor activity suggests this as well. 
     In summary, the intent with this first experimental set was to ensure that peripherally-
administered LPS induced a full peripheral immune response to which the effects of 
peripherally-administered IL-1β could be compared.  The behavioural and physiological 
changes observed following the peripheral administration of LPS confirms that LPS does 
initiate a sickness response indicative of peripheral immune activation.  In addition, the 
peripheral administration of IL-1β also induces central effects, thereby allowing the 
inference that any absence of effects on cognition observed following IL-1β 
administration is not due to an inability of the compound to effect a central response, but 
rather is an inability of the compound to effect changes specific to cognition. Also, 
because both compounds reliably induce several sickness behaviours, effects of LPS and 
/ or IL-1β on learning and memory can be dissociated from other sickness behaviours.  If 
LPS induces a learning and memory deficit that is not present following the peripheral 
administration of IL-1β, then the learning deficit is likely not secondary to other illness 
processes.  
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 Learning and Memory (Experiments 3-7) 
Introduction 
     The purpose of this second set of experiments is to determine the role of peripheral IL-
1β in cognitive disruption, as well as to determine the cognitive processes that are 
disrupted by the peripheral inflammatory response. 
     To date, most of the investigation into sickness-induced cognitive dysfunction has 
focused on the effects of LPS and IL-1β on hippocampal learning and memory systems.  
The hippocampus is a target worthy of investigation into sickness-induced cognitive 
dysfunction, not only because the hippocampal system is widely held to be integrally 
involved in numerous aspects of cognition, including configural learning (Rudy & 
Sutherland, 1989; Sutherland, McDonald, Hill, & Rudy, 1989); spatial navigation 
(Holscher, 2003 ( review)); and visual discrimination, or object recognition (Nakamura & 
Kubota, 1996 (review)); but also because IL-1β receptors are up-regulated in the 
hippocampus following pathogen exposure, such as following exposure to LPS (Nagano, 
Takao, Nanamiya, & Hashimoto, 2000) or the envelop glycoprotein for the Human 
Immunodeficiency Virus ((HIV-1, gp120) Pugh et al., 2000).  For these reasons, the 
majority of experiments investigating the effects of IL-1β and LPS on learning and 
memory involve the measurement of performance on tasks that require (i.e., sensitive to 
insult) the hippocampus. 
     Two learning and memory tasks demonstrated to require an intact hippocampus are 
the Morris water task ((Morris, 1981) Morris, Garrud, Rawlins, & O’Keefe, 1982; 
Sutherland, Kolb, & Wishaw, 1982; Sutherland, Wishaw, & Kolb, 1983) and      
contextual fear conditioning (Sutherland & McDonald, 1990; Opp, Obal, & Krueger, 
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 1991; Seldon, Everitt, Jarrard, & Robins, 1991; Kim & Fanselow, 1992; Philips & 
LeDoux, 1994; 1995).  The Morris water task is a spatial learning and memory task in 
which animals are trained to use distal cues to find their way to a submerged platform 
hidden in a circular pool of opaque water.  The animal is released from different starting 
locations within the pool (NSEW), and so must learn to use the configural relationships 
among the different cues in the room to navigate to the platform successfully.  This 
ability to navigate through an environment using topographical relationships among 
different objects within the environment has been demonstrated to be dependent upon the 
hippocampal formation, as animals with hippocampal damage show severe impairments 
in their ability to navigate to the submerged platform (Morris et al., 1982; Sutherland et 
al., 1992; 1993).  
     In the contextual fear conditoning task, animals are conditioned to associate both a 
context and auditory tone with a foot shock.  The animals’ retention for the context and 
tone are later assessed, via the assessment of the animals’ fear response (freezing) to 
either the tone (auditory-cue fear conditioning) and / or the context (contextual fear 
conditioning).  Typically, a conditioning chamber consists of a clear, plexi-glass ceiling, 
four walls, and a floor consisting of stainless-steel rods.  By removal of the floor and / or 
the insertion of plastic sides to cover the clear walls, the context can be altered.  This 
alteration permits the dissociation of context and tone retention, which, in turn, allows for 
the clear identification of hippocampal-specific effects of a treatment.  An intact 
hippocampus is necessary to successful task performance through its proposed ability to 
store a representation of a set of features bound into a unitary representation, referred to 
as a conjunctive representation (Rudy & O’Reilly, 2001 (review)).  This proposal is 
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 supported by observations that animals with hippocampal damage exhibit selective 
impairments in retention for the original context in which they had experienced the 
shock, but show normal retention for the tone presented in an alternate environment 
(Opp, Obal, & Krueger, 1991; Jarrard, & Robins, 1991; Kim & Fanselow, 1992; Philips 
& LeDoux, 1994; 1995).  This dissociation suggests that animals with compromised 
hippocampal functioning are impaired specifically in their ability to create and store 
representations of contextual information, not in their ability to retain information 
regarding the aversive quality of the shock, or their ability to mount an appropriate fear 
(i.e., freezing) response.       
     The use of the contextual fear conditioning task also allows for the additional 
dissociation of the animals retention specifically for the context from the animals’ 
retention for the aversive quality of the shock within the context.  The ability to construct 
a representation of the features and the ability to associate this representiation with the 
aversive qualities of the shock are held to constitute two distinct processes, with only the 
former demonstrated to depend on the hippocampus (Young, Boheneck, & Fanselow, 
1993; Rudy, 1996; Pugh, Tremblay, Fleshner, & Rudy, 1997;  Pugh et al., 1998; 
Barrientos et al., 2002).  The dissociation between the two processes can be made by 
briefly (i.e, couple of minutes) pre-exposing the animals to the context in which they will 
later receive the foot shock.  Pre-exposure presumably allows the animal to acquire a 
stable representation of the environment, as several studies have demonstrated that 
impairments in context retention that had been previously observed following 
hippocampal damage and / or insult, were abolished if the animals were pre-exposed to 
the context prior to damage and / or insult (Young et al., 1993; Rudy, 1996; Pugh et al., 
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 1997, 1998; Barrientos et al., 2002).  It has been proposed, and supported with data, that 
the hippocampus is necessary to the beneficial effects of brief pre-exposure through its 
ability to acquire a conjunctive representation of the context (Rudy & O’Reilly, 1999; 
Rudy, Barrientos, & O’Reilly, 2002).  Therefore, the use of the contextual fear 
conditioning task can be used to reveal learning and memory effects that are specific to 
effects on hippocampal functioning, as well as to identify non-hippocampal treatment-
induced effects.  
     Available data do not provide for a clear picture of which, if any, cognitive processes 
are impaired by the peripheral inflammatory response, as it is induced by the 
administration of endotoxin.  In one of the few studies to investigate the effects of 
peripherally administered LPS on Morris water task performance in the rat, Shaw and 
colleagues (2001) observed a LPS-induced inhibitory effect on latency to reach the 
platform on days four and eight following a single LPS injection (100 μg/kg).  However, 
this inhibitory effect was not observed on any other of the testing days, making difficult 
the extraction of any meaningful conclusions.  Furthermore, Shaw et al. (2001) used a 
fixed release point in their training protocol.  This is important because the use of a fixed 
release point does not require the animal to alter its swim path in accordance with extra-
maze cues.  In fact, Eichenbaum and colleagues (1990) demonstrated that animals with 
hippocampal damage can perform as well on the fixed-start version of the Morris water 
task as control animals. To conclude, then, the data provided by Shaw et al. (2001) 
suggest that peripherally-administered LPS may disrupt Morris water task performance 
via a LPS-induced inhibition of hippocampal learning and memory systems, but they 
cannot be considered strong support for the proposal. 
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      The strongest evidence of a process-specific effect of LPS on learning and memory 
comes from a series of experiments on Pavlovian contextual fear conditioning conducted 
by Pugh and colleagues (1998).  Pugh et al. observed that peripheral administration of 
LPS immediately after conditioning impaired retention of contextual fear, but not fear of 
an auditory-cue.  This dissociation suggests that LPS disrupts a hippocampal-specific 
learning and memory process.  Furthermore, Pugh and colleagues report that brief pre-
exposure to the context eliminated the inhibitory effect of LPS on context retention. 
However, this impairment re-emerged if LPS was administered immediately after the 
context pre-exposure.  Taken together, these results suggest that LPS disrupts a short-
term, post-trial memory consolidation process.  Because context pre-exposure eliminated 
the inhibiting effect LPS had on context retention, LPS appears to specifically disrupt a 
hippocampal-dependent ability to acquire a representation of the context, and not the 
animal’s ability to retain a representation of the aversive quality of the shock (Young et 
al., 1993; Rudy, 1996; Pugh et al., 1997, 1998; Barrientos et al., 2002).  This evidence, 
then, suggest that LPS interferes with retrograde (i.e., memories acquired immediately 
prior to endotoxin administration) and not with anterograde (i.e., memories acquired 
following endotoxin administration) learning and memory processes.  It appears 
necessary, then, to separately assess the effects of LPS on these two processes in the 
Morris water task.   
     In addition to the clarification of the cognitive processes that are disrupted by the 
administration of endotoxin and the consequent peripheral inflammatory response, it is 
necessary to determine if the proinflammatory cytokine IL-1β is the primary peripheral 
signaling molecule of sickness-induced cognitive dysfunction.  Evidence exists to suggest 
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 that IL-1β is the primary central signaling molecule of sickness-induced cognitive 
dysfunction.  Animals who received an intracerebroventricular (i.c.v) administration of 
IL-1β one hour prior to training in a fixed-platform version of the Morris water task 
showed longer latencies to reach the hidden platform the following day (Oitzl, van Oers, 
Schobitz, & de Kloet, 1993).  However, because the  cytokine was administered prior to 
the training episode, it cannot be concluded whether central IL-1β disrupts acquisition or 
retention.  A later study conducted by Barrientos and colleagues (2002) suggests that 
central IL-1β impairs learning and memory by disrupting memory consolidation.  
Barrientos et al (2002) observed that animals who received an injection of IL-1β into the 
dorsal hippocampus immediately following a brief pre-exposure to the environment in 
which they would receive a foot shock, later showed impaired retention for the context.  
These observations suggest that, not only does central IL-1β inhibit a hippocampal-
dependent learning and memory process, but that IL-1β may also be the central signaling 
molecule of the post-trial consolidation-specific effect of LPS that had been earlier 
observed by Pugh and colleagues (1998).  
     Peripherally, the actions of IL-1β on hippocampal learning and memory systems are 
not clear.  Gibertini and colleagues (1995) observed an inhibitory effect of peripherally-
administered IL-1β on Morris water task performance in mice.  Using a fixed-platform 
version of the task, Gibertini peripherally administered IL-1β prior to training on two 
consecutive days.  After being left unperturbed for a week, the IL-1β-injected animals 
were slower to reach the hidden platform. However, because Gibertini et al., (1995) 
administered IL-1β prior to training, effects of peripheral IL-1β on learning cannot be 
dissociated from IL-1β effects on retention.    Moreover, a later experiment by the same 
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 group (Gibertini, 1998) revealed that IL-1β-injected animals were no longer impaired in 
their ability to locate the hidden platform using a different training protocol, water 
temperature, or dose.  A spaced training protocol (i.e., greater delay between training 
blocks), colder pool water, and a higher dose of IL-1β did not induce longer escape 
latencies in the animals during retention testing (Gibertini, 1998).  Therefore, if 
peripheral IL-1β is sufficient to induce learning and memory impairments, the 
impairments may not be global nor robust.   
     Importantly, the effects of peripherally administered IL-1β on Morris water task 
performance in rats have not yet been investigated.  Because differences in performance 
in the Morris water task have been observed within strains of a species (Klapdor & van 
der Staay, 1996; Gleason, Dreiling, & Crawley 1999) and across species, such as the 
mouse and the rat (Frick, Stillner, & Berger-Sweeney, 2000), the effects of peripherally 
administered IL-1β on Morris water task performance in the rat should be investigated 
prior to forming any conclusion regarding the role of peripheral IL-1β in sickness-
induced cognitive dysfunction. 
     Taking the foregoing observations into consideration, it appears necessary to address 
the question of the key components, and key cognitive consequences, of the peripheral 
inflammatory response more systematically than has been done previously.  First, it is 
necessary to distinguish anterograde from retrograde learning and memory effects 
induced by LPS and / or IL-1β.  Second, it is necessary to compare the effects of the two 
compounds across learning and memory paradigms. It is possible that one or both 
compounds might have an effect on performance in a task, such as the contextual fear 
conditioning task that assesses configural learning and memory, but not on performance 
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 in a task, such as the Morris water task that assesses the ability to use configural 
associations to accurately navigate to a hidden target.  In order for results to successfully 
converge on a single hippocampal-depended process, similar impairments in both tasks 
would be necessary.  The pattern of results should reveal which cognitive processes are 
sensitive to the peripheral inflammatory response, as it is induced by LPS, and whether 
the peripheral actions of IL-1β, alone, are sufficient to trigger similar changes. 
     These questions are addressed in the following experimental set (Experiments 3 – 7).  
In Experiments 3 and 4, the effects of peripheral LPS and IL-1β are measured on post-
trial memory consolidation processes in the Contextual fear conditioning task.  If LPS 
disrupts post-trial memory consolidation processes, then LPS, administered immediately 
after conditioning, should inhibit context retention (replicating Pugh et al., 1998).   If IL-
1β is the primary peripheral signaling molecule of this effect, then a similar impairment 
in context retention should be observed following peripheral IL-1β administration. 
     In Experiments 5-7, the effects of peripherally-administered LPS and IL-1β on 
learning and memory performance in the Morris water task are assessed in both the 
anterograde and retrograde directions.  If sickness-induced cognitive dysfunction is a 
robust memory consolidation-specific effect, an impairment should also be evident in 
animals who are administered LPS following the acquisition of new spatial location 
information.  In addition, if IL-1β is the primary peripheral signaling molecule of this 
effect, then IL-1β -treated animals should exhibit a similar performance deficit. 
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 Experiments 3 & 4:  LPS and IL-1β Effects on Contextual Fear Conditioning 
Methods 
     Apparatus.  Testing chambers were supplied by Med Associates Inc (MED-AFC-R1).  
Each chamber (25.4 cm L X  31.8 cm W X  22.9 cm H ) consisted of:  removable floors 
of stainless steel rods  (0.5 cm in diameter,  spaced  1.0 cm apart), a metal floor pan, and 
a speaker through which a 1000 Hz tone was presented (conditioning and tone retention).  
A 2 s. 1.0 mA shock was delivered through the rods.  The chambers were altered during 
tone retention testing by removing the floor rods and inserting three white plastic panels 
to cover the clear plexi-glass top and two sides of the chamber.  Additionally, the ambient 
light in the room was dimmed.  A video camera that delivered images to data analysis 
software was placed approximately 1.5 meters from the chambers.  Chambers were 
disinfected between trials.   
     Data analysis.  Freezeframe (Actimetrics, Inc.) software was used to acquire video 
images of the animals and to quantify each animal’s freezing response.  As recommended 
by the software developers, the freezing threshold was chosen by examining motion 
index histograms generated for each animal and determining the value at which the 
trough in the histogram met the broad peak (represents activity).  After each trial was 
individually reviewed to ensure that one value was valid for all animals, a freezing 
threshold of 20 was chosen.  This value was within the range (20-30) recommended by 
the software developers. 
      Drugs.  In Experiment 3, lipopolysaccharide (LPS Ecoli 026:B6); Sigma, Lot no. 
101K4080; 3 million endotoxin units per MG) was injected i.p. at doses of 2μg/kg and 
4μg/kg.  These doses were matched, based on endotoxin levels, to the doses used by Pugh 
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 et al. (1998).  In Experiment 4, doses of IL-1β were chosen to incorporate a wide (albeit 
not all-inclusive) dose range, including a low, moderately-low, moderate, and high dose.  
Human recombinant interleukin-1beta ((hrIL-1β) Research Diagnostics Inc.(RDI); 
catalog no. RDI-201b) was injected i.p. at doses of:  .1 μg/kg (low), 2 μg/kg (mod-low), 4 
μg/kg (mod), and 100 μg/kg (high).  All vehicle controls received i.p. injections of an 
equivalent volume of sterile, pyrogen-free saline (Abbot Laboratories, Lot no. 79-613-
DM-01). 
     Procedure.  Eighteen (6 per group) animals were used in Experiment 3 and thirty-five 
animals (seven per group) were used in Experiment 4.  The experiments were conducted 
during the light cycle, between 09:00 and 14:00.  The same procedure was used for both 
experiments.  During the conditioning period, animals were placed in the conditioning 
chamber for five minutes.  Two tone-shock pairings were presented during this time, one 
at 120 s. and one at 400 s.  For each pairing, a two-second shock was presented during 
the last two seconds of a twenty-second tone.  Following the second tone-shock 
presentation, animals were left in the chamber for 30 s. before being removed.  
Immediately upon removal, animals were injected with:  Experiment 3:  2 μg/kg LPS, 4 
μg/kg LPS, or saline; Experiment 4: .1 μg/kg IL-1β, 2 μg/kg IL-1β, 4 μg/kg IL-1β, 100 
μg/kg IL-1β, or saline.  Following injections, animals were returned to their home cage. 
      Retention for the context and tone was tested 48 hours following the conditioning 
period, allowing time for any direct effects of the injections to dissipate.  Context 
retention testing was conducted prior to tone retention testing.  During context retention 
testing, animals were placed into the original conditioning chamber for five minutes.  
After all animals had been tested for context retention, they were placed into the altered 
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 chamber for six minutes to test for tone retention, during which the original tone was 
absent for the first three minutes of testing and present during the last three minutes of 
testing.  Following the cessation of tone retention testing, all animals were returned to 
their home cage. 
Results 
     Experiment 3.  In an attempt to directly replicate the dose-specific effects of LPS on 
context retention as observed by Pugh et al. (1998), planned t-test were conducted on the 
percentage of time spent freezing during context retention for both the 2 μg/kg LPS and 
saline-treated groups, and the 4 μg/kg LPS saline-treated groups.  As Figure 7 depicts,     
a significant impairment in context retention was observed in animals treated with 2 
μg/kg of LPS (t(10 ) = 2.67; p <  . 05) compared to saline-treated controls.  The 2 μg/kg 
LPS dose resulted in roughly a 40 percent decrease in freezing behaviour (M(saline) = 
68%, M(2 μg/kg LPS) = 43%).  A context retention impairment was not observed in 
animals treated with 4 μg/kg of LPS (t(10 ) = 0.95; p >  . 05) compared to saline-treated 
animals, though these animals showed a decreased mean freezing response (non-
significant) compared to saline-treated controls (MU(4 μg/kg) LPS = 54%).  When both 
LPS-treated groups were combined (n = 12) and compared to the saline-treated animals 
in Experiments 3 and 4 (n = 13), a significant impairment in context retention was 
similarly observed in the LPS-treated combined group (t(23) = 2.42, p < .05). 
     As depicted in Figure 8, no differences were observed among groups in their freezing 
response prior to and during the presentation of the tone as revealed by an absence of a 
group-by- time effect (F(1,15) < 1, p > .05).  However, all animals froze significantly 
more during the presence of the tone, as revealed by a significant effect of time ((pre- 
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 and-post tone presentation) (F(1,15) = 61, p < .001).  Furthermore, a repeated-measures 
test on the combined data (2 μg/kg + 4 μg/kg LPS vs. Exp. 3 & 4 saline-treated animals) 
revealed similar effects, with an absence of a group-by- time effect (F(1, 30) = 000.22, p 
> .05) and the presence of a significant effect of time (F(1, 30) = 159.93, p < .001). 
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Figure  7.  Retention for context 48 hours post-LPS.   Mean and SEM of percentage of  time spent freezing in original     
   context are depicted for animals injected with:  2 μg/kg LPS, 4 μg/kg LPS, or saline..   *Significant difference between        
                 2 μg/kg LPS and controls ( p <   .05).    
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Figure 8.  Retention for tone 48 hours post-LPS.  Mean and SEM of percentage of time spent freezing before and after tone 
presentation for animals injected with:  2 μg/kg LPS, 4 μg/kg LPS, or saline.  No significant differences among groups 
 (p > .05). 
 
 
     Experiment 4.  As depicted in Figure 9, no differences were observed among groups 
in their freezing response to the context (F(4, 37) = 1.27, p >.05).  In addition, as depicted 
in Figure 10, no differences were observed among groups in their freezing response prior 
to and during the presentation of the tone (F(4, 37) < 1, p > .05) , with all animals 
freezing significantly more during the presentation of the tone (F(4, 37) = 174, p < .001).   
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Figure  9.  Retention for context 48 hours post-IL-1β.   Mean and SEM of percentage of time spent freezing in original context are 
depicted for animals injected with:  .1 μg/kg IL-1β, 2 μg/kg IL-1β, 4 μg/kg IL-1β, 100 μg/kg IL-1β, or saline.  No significant 
differences observed among groups (p > .05).        
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Fig. 10.  Retention for tone 48 hours post-IL-1β.  Mean and SEM of percentage of time spent freezing before and after tone 
presentation for animals injected with:  .1 ug/kg IL-1β, 2 μg/kg IL-1β, 4 μg/kg IL-1β, or saline.  No significant differences among 
groups (p > .05). 
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 Conclusions:  Experiment 3 & 4 
     Animals injected with a 2μg/kg LPS dose exhibited a significant impairment in 
context retention compared to the saline-treated animals, replicating effects observed by 
Pugh and colleagues (1998). Unlike Pugh and colleagues (1998), however, a significant 
inhibition of freezing behaviour in response to the original context was not observed in 
the animals treated with the higher dose of LPS (4μg/kg LPS), though these animals did 
exhibit a non-significant inhibitory trend.  The difference in results could derive from 
differences in biological activity of the compound across batches, despite having been 
matched for equivalent endotoxin levels (Sigma Aldrich, technical support, scientific 
communication).    
     Because the hippocampus appears to be necessary to context retention and not to the 
retention and / or expression of fear, (Opp et al., 1991; Seldon et al., 1991; Kim & 
Fanselow, 1992; Philips & LeDoux, 1994; 1995), these results suggest that LPS, at 
certain doses, specifically disrupts hippocampal-dependent post-trial memory 
consolidation processes.  The observation of a non-significant trend toward inhibition in 
the animals treated with the higher dose of LPS suggests that there may be a U-shaped 
dose-response relationship between LPS and memory consolidation, with moderate doses 
inhibiting memory more than lower or higher doses.  Indeed, this type of relationship has 
been suggested by other researchers.  Pugh and colleagues (1998) demonstrated that, 
whereas two of their two tested doses (.125 mg/kg, .25 mg/kg) inhibited context 
retention, animals injected with saline or a higher LPS dose (.5 mg/kg) showed normal 
context retention. 
     Unlike the LPS-treated animals, animals injected with four different doses- 
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  .1 μg/kg, 2 μg/kg, 4 μg/kg, and 100 μg/kg- of IL-1β did not exhibit any significant 
differences in freezing behaviour during context retention testing compared to the saline-
treated animals.  A non-significant trend in inhibition of freezing behaviour during 
context retention was observed in the animals treated with 2 μg/kg of IL-1β, suggesting 
that systemic IL-1β may have an inverted-U dose-response relationship to learning and 
memory similar to LPS.  This observation is consistent with previous observations that 
low levels of the pro-inflammatory cytokines are necessary for learning and memory 
(Gibertini, 1998; Yirmiya, Wincour, & Goshen, 2002; Brennen, Beck, & Servatius, 
2003).  It is plausible that moderate doses of systemic IL-1β - though not sufficient to 
impair learning and memory- are more likely than other dosage levels to impair learning 
and memory. 
     In summary, LPS, at low-moderate doses, disrupts memory consolidation.  IL-1β 
showed a non-significant U-shaped relationship between dose and inhibition of memory 
consolidation.  However, IL-1β, alone, is insufficient to cause reliable inhibition. As 
previously described, LPS is a potent endotoxin that induces the release of several 
proinflammatory cytokines in addition to IL-1β, such as IL-6 and tnf-α (Rietschei & 
Brede, 1992; Kakizaki, Watanobe, Kohsaka, & Suda, 1999). It is plausible, then, that the 
synergistic actions of these cytokines are required in the periphery to cause the inhibition 
of memory consolidation that we, and Pugh et al. (1998), observed. 
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Experiments 5-7:  LPS and IL-1ß Effects on Morris water task Performance  
Methods 
     Apparatus.  The Morris water task apparatus consisted of a pool (1.5m diameter) filled 
to within 20 cm of the top of the wall with water (20 +10 C) that was rendered opaque by 
skim milk powder.  The wall of the pool was uniformly white.  In addition, the pool was 
located in a room rich with distal cues, which remained intact and unobstructed 
throughout the duration of the experiment.  During the hidden platform trials, a hidden 
platform, constructed of clear plexi-glass (13 X 13 cm), was submerged 1.5 cm under the 
surface of the water.   
     In all experiments, each trial began with the rat being placed in the pool at one of the 4 
cardinal compass positions around the perimeter of the pool according to a pseudo-
random sequence, such that each starting location was used once per block of four trials.  
The maximum duration of each swim trial was 60 seconds (s.).  If the rat found the 
platform within this 60 s. period, it was allowed to remain on the platform for 8 
additional seconds.  If it did not find the platform during the allotted time, then it was 
manually placed onto the platform for 8 s, before being placed back into its holding cage.  
Following each swim trial, each rat was placed back into a holding cage where it was 
allowed to rest for at least five minutes before the start of the next swim trial. 
     Data analysis.  Data were collected using a video camera + Windows-based 
microcomputer automated system, which included a HVS Image Analysis system with 
video monitoring and storage capabilities. In addition to overall latencies to find the 
platform, the system calculated:  total swimming path distance, initial heading direction 
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 (after swimming 13 cm), and proportion of swimming in each quadrant of the pool.  The 
main outcome measure used for all experiments was the average latency of each group to 
navigate to the hidden platform. In addition, probe and visible platform trials were 
conducted for each experiment.  For the probe trial, the platform was removed from the 
pool and each animal was allowed to swim for 30 s. before being removed from the pool.  
The percentage of time the animal spent in the quadrant in which the platform had been 
previously located was calculated for each animal.  For the visible platform trial, the pool 
was drained approximately 3.0 cm so that the platform could be seen by the animals.  It 
was placed directly across from one fixed release point and one trial was conducted for 
each animal. The visible platform trial was used as a non-hippocampal-dependent control 
task, as well as to control for any sensori-motor effects that could be induced by either or 
both of the compounds.  The time to mount the visible platform was used as the 
dependent variable. 
     Drugs.  In the following experiments, lipopolysaccharide (LPS Ecoli 026:B6); Sigma, 
Lot no. 101K4080; 3 million endotoxin units per MG) was injected intraperitoneally (i.p.) 
at doses of 2μg/kg (Experiment 5) and 100 μg/kg (Experiment 6). Human recombinant 
interleukin-1beta (hrIL-1β) was injected i.p at a dose of 2 μg/kg for all experiments 
(explanations for the dosage levels are provided in the procedure sections for each 
experiment).  For Experiment 5, the cytokine was purchased from Research Diagnostics 
Inc.((RDI) catalog no. RDI-201b), and for Experiments 6 and 7, the cytokine was 
generously donated by the National Institutes of Health National Cancer Institute 
Biological Resources Branch  (NIH NCI BRB) Preclinical Repository.  The compounds 
were determined to have equivalent in vivo biological activity.  All vehicle controls 
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 received i.p. injections of an equivalent volume of pyrogen-free saline (Abbot 
Laboratories, Lot no. 79-613-DM-01). 
     Procedure:  Experiment 5.  A moving platform protocol was used in Experiment 5 to 
test the effects of peripherally-administered LPS and IL-1β on post-trial memory 
consolidation of spatial location information.  This experiment was conducted in order to 
test whether the LPS-induced inhibitory effect in memory consolidation of context 
conditioning, observed in the previous experiment, generalized to an inhibition in 
memory consolidation in a spatial navigation task.  In this experiment, animals (N = 21, 7 
animals per group) were initially trained for five days, with one block of trials a day (4 
trials per rat), to locate a hidden platform that was moved every other day to a new 
location within the pool.  So, the sequence was:  Day 1(new), Day 2(same), Day 3(new), 
Day 4(same), Day 5(new).  Immediately following the completion of the fourth trial on 
the fifth day, animals were injected with:  2μg/kg of LPS, 2μg/kg of IL-1β, or pyrogen-
free saline.  These doses were based on observations from the previous experiment 
(Experiment 3) that these doses were most likely to inhibit memory consolidation.  In 
addition, these doses have been previously demonstrated to induce symptoms of sickness, 
such as fever (Yirmiya, Tio, & Taylor, 1996).  Following injections, animals were 
returned to their home cage and allowed to rest for 24 hours. 
     On testing day, all animals were first subjected to a probe trial in which the percentage 
of time spent in the quadrant in which the platform was located on Day 5 was calculated 
and used as the dependent variable.  Following the completion of the probe trial, all 
animals received an additional block of trials (4 trials/rat) during which they had to locate 
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 the platform, hidden in the same location as Day 5.  Finally, all animals performed a 
visible platform trial. 
      Procedure:  Experiment 6. Whereas experiment 5 tested the effects of LPS and IL-1β 
on retrograde learning and memory processes (i.e, memory consolidation), experiment 6 
tested the effects of both compounds on anterograde learning and memory processes.  In 
this experiment, animals were injected with either LPS or IL-1β prior to having to learn 
the location of a new platform location.  Two separate groups of animals were run in this 
experiment (group 1 receiving LPS (N = 10, 5 animals per group); group 2 receiving IL-
1β (N = 12, 6 animals per group).  However, because the experimental procedure for both 
experiments was identical, both data sets are included in this section. 
     In Experiment 6, animals were trained to navigate to a hidden platform that was 
moved daily to a different location in the pool.  Each animal received 1 block (4 trials) of 
training per day.  Animals were trained until their average escape latencies reached 
asymptote.  On testing day, animals were injected with:  100 μg/kg of LPS, 2 μg/kg of 
IL-1β, or an equi-volume amount of pyrogen-free saline.  A higher dose of LPS was used 
in this experiment in an attempt to replicate Shaw et al. (2001) who had observed the 
previously discussed inhibitory effect of LPS at this dose on ability to learn the location 
of the platform in the Morris water task.  At one hour, animals were required to navigate 
to a recently-moved hidden platform.  A block of 4 trials was conducted in which the 
difference between the average escape latencies for trials 1 and 2 was calculated for each 
animal and averaged across treatment groups.  In addition, probe and visible platform 
trials were conducted upon the completion of the fourth trial.   
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      Additional testing was conducted for four days following injections in an effort to 
replicate Shaw et al. (2001) who observed a LPS-induced inhibitory effect on Day 4 
performance.   
     Procedure:  Experiment 7.  A fixed platform version of the Morris water task was used 
in this experiment to test the effects of peripherally-administered IL-1β on the retention 
of a well-learned spatial location.  Because evidence suggests (Gibertini et al, 1995) that 
IL-1β might interfere with the retention of spatial location information, effects were 
measured of peripherally-administered IL-1β on retention of a platform’s location after it 
had been well-learned over a course of several days.  Animals (saline = 4 animals, IL-1β 
= 5 animals ) were trained to find the location of a fixed hidden platform until their 
average escape latencies reached asymptote.  On testing day, animals were injected with 
2 μg/kg of IL-1β or an equivalent volume of pyrogen-free saline.  Again, this dose of IL-
1β was chosen because there was a non-significant trend observed in memory 
consolidation in Experiment 3.  Approximately 75 minutes following injections, animals 
were tested over the course of four trials (1 Block) to locate the hidden platform.  After 
the completion of the block, both probe and visible platform trials were conducted. 
Results 
     Experiment 5.  As Figure 11 depicts, no significant differences were observed among 
treatment groups in their ability to successfully navigate to the platform during trials 1 
through 4.  A one-way analysis of variance (ANOVA) on the percentage of time spent in 
the quadrant in which the platform had been located the previous day revealed the three 
treatment groups averaged approximately the same amount of time of the 30 second  
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 probe trial in the correct quadrant (F (2,18) = .38, p > .05; M(saline) = 36 %; M (IL-1β) = 
40 %; M(LPS) = 33 %).  In addition, a repeated-measures ANOVA revealed that, though 
all treatment groups evidenced learning over the course of the four trials, as indicated by 
a significant effect of trial (F(2, 18) = 7.92, p < .01), no differences were observed among 
groups in their ability to locate the platform, as evidenced by the absence of a treatment 
effect (F(2, 18) = 2.46, p > .05) or of a trial by treatment interaction (F (2,18) = .17, p > 
.05). 
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Figure 11.   Effects of LPS and IL-1β on post-trial memory consolidation.  Mean and SEM of average escape latency (sec  to reach 
platform) are depicted for animals injected with:  2 μg/kg IL-1β, 2 μg/kg LPS, or saline. .No significant differences among groups (p > 
.05). 
 
       
     Experiment 6.  As Figures 12 and 13 depict, both saline and LPS – treated animals 
were able to learn the location of the moving platform equally well.  A paired-samples t-
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 test revealed no significant differences in the difference in escape latencies for trials one 
and two between groups, neither an hour following (t (9) = -1.59, p > .05), nor twenty-
four hours following  (t (9) = -1.18, p > .05) injections.  
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Figure 12.  Effects of LPS on acquisition of new platform location 1 hour following injection.  Mean and SEM of average escape 
latency (sec.) are depicted for animals injected with 100 μg/kg of LPS or an equi-volume amount of pyrogen-free saline.  No 
significant differences among groups( p > .05). 
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Figure 13.  Effects of LPS on acquisition of new platform location 24 hours following injection.  Mean and SEM of average escape 
latency (sec.) are depicted for animals injected with 100 μg/kg of LPS or an equi-volume amount of pyrogen-free saline.  No 
significant differences among groups (p > .05). 
 
     Similar performance in LPS and saline-treated animals was observed for four days 
following injection; no differences were observed between groups (data not shown).      
     As depicted in figures 14 and 15, IL-1β and saline-treated animals also performed 
equally well.  A paired-samples t-test revealed no significant differences in the difference 
in escape latencies for trials 1 and 2 between groups, neither an hour following (t (11) = 
.20, p > .05), nor twenty-four hours following  (t (11) = -.32, p > .05) injections. 
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Figure 14.  Effects of IL-1β on acquisition of new platform location 1 hour  following injection.  Means and SEM of average   
escape latency (sec) are depicted for animals injected with 2μg/kg of IL-1β or an equi-volume amount of pyrogen- 
 free saline.   No significant differences observed between groups (p > .05). 
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 Figure 15.  Effects of IL-1β on acquisition of a new platform location 24 hours following injection.  Mean and SEM 
 of average escape latency (sec) are depicted for animals treated with 2μg/kg of IL-1β or an equi-volume amount of pyrogen- 
 free saline.  No significant differences observed between groups (p > .05). 
      
     Experiment 7.  As depicted in figures 16 and 17, IL-1β- and saline treated animals 
were both equally able to retain the well-learned location of the hidden platform.  No 
differences were observed between groups in their ability to locate the platform one hour 
following injections, as evidenced by the absence of a treatment effect  (F(1, 8) = .68, p > 
.05), or of a trial by treatment interaction  
(F (3,6) = .63, p > .05).  The two groups also produced similar escape latencies 24 hours 
following injections, as evidenced by the absence of a treatment effect,   
(F(1, 8) = 1.10, p > .05), or of a trial by treatment interaction (F (3,6) = 2.29 p > .05).    
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Figure 16.  Effects of IL-1β on retention for a fixed platform 1 hour following injection.  Mean and SEM of average escape latency are 
depicted for animals injected with 2 ug/kg of IL-1β or an equi-volume amount of pyrogen-free saline (p > .05). 
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Figure 17.   Effects of IL-1β on retention for fixed platform 24 hours following injection.  Mean and SEM of the average escape 
latency are depicted for animals treated with 2μg/kg of Il-1β or pyrogen-free saline (p > .05). 
 
 
Conclusions:  Experiments 5-7 
     Data from Experiments 5-7 demonstrate that animals are able to acquire and maintain 
spatial information quite well.  The observation that both IL-1β and LPS-treated animals 
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 performed as well as saline-treated control animals suggests that neither compound acts 
peripherally to interfere with these abilities.   
      The impairments observed in the LPS-treated animals in Experiment 3 did not 
generalize to the Morris water task.  As observed in Experiment 5, animals treated with 
the same dose of LPS as used in Experiment 3 using the contextual fear conditioning task 
did not show impairments in their ability to locate the platform the following day.  
Because the animals were injected with LPS immediately after a training block in which 
they had to learn the location of a recently moved hidden platform, the effects of LPS on 
immediate memory consolidation presumably are restricted to the contextual fear 
conditioning task.  Explanations for this dissociation are discussed at the end of this 
paper. 
     Experiments 6 and 7 were attempts to replicate, using a a proper random release 
schedule, a previous observation that LPS interferes with acquisition of new spatial 
location information (Shaw et al., 2001), and another observation that IL-1β interferes 
with the retention of well-learned spatial location information (Gibertini et al., 1995).  
The data from both experiments did not support either scenario.  LPS-treated animals 
performed at a level on par with saline-treated animals in their ability to successfully 
learn the new location of a hidden platform; and furthermore, these animals were just as 
able as the saline-treated animals to retain information regarding the new location across 
the remaining three trials in the block.  One difference in the present protocol compared 
to that used by Shaw and colleagues (2001) was the use of random release points.  It is 
possible that the impairment observed by Shaw et al (2001) was caused by an extra-
spatial processing impairment in LPS- treated animals that became occluded when the 
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 animals were subjected to the presumably more difficult, hippocampal-dependent spatial 
task used in these experiments. 
     In comparison to Gibertini and colleagues (1995), a deficit was not observed in IL-1β- 
treated animals in long-term retention version of the Morris water task.  Unlike Gibertini 
et al. (1995), Long-Evans rats were used rather than mice.  Also unlike Gibertini et al. 
(1995), animals were trained for more days prior to injection.  This longer training 
schedule is necessary to be able to separately assess IL-1β effects on memory retention 
from consolidation.  Though the time course of hippocampal-dependent consolidation 
and long-term retention processes is a hotly debated ongoing theme in the learning and 
memory field, asymptotic escape latencies are a well-recognized behavioural marker that 
animals have successfully learned the task.  It can be reasonably concluded, therefore, 
that IL-1β, when it is administered after animals have acquired a stable memory of a 
hidden platform location, does not interfere with the ability to successfully navigate 
toward this location. 
      Novel testing of IL-1β on memory consolidation in the Morris water task 
(Experiment 5) and on acquisition of a new location in the Morris water task (Experiment 
6) revealed no significant IL-1β-induced effects.  The absence of an impairment in 
memory consolidation in the Morris water task is consistent with the absence of an 
impairment in the contextual fear conditioning task, as observed in Experiment 4. The 
absence of an IL-1β-induced impairment on acquisition in the Morris water task suggests 
IL-1β similarly does not interfere with new learning. 
     In contrast to the limited number of previous experiments that have investigated the 
effects of peripherally-administered IL-1β or LPS on Morris water task performance, 
 54
 Experiments 5 through 7 were designed to separately assess:  the ability to learn the new 
location of a moving hidden platform (acquisition); the ability to retain well-learned 
information regarding the location of a fixed platform (retention), and the ability to 
consolidate new spatial information after peripheral LPS or IL-1β administration.  These 
functionally distinct memory processes have been assessed using appropriate training (i.e, 
duration) and testing (i.e, random release points) methods, with no effects on learning and 
memory evident following neither LPS nor IL-1β administration.  Importantly, doses that 
were previously demonstrated in Experiments 1 and 2 to make an animal ill, did not 
cause deficits in learning and memory in the present set of experiments.  In addition, 
doses that were lower than those tested in Experiments 1 and 2, but which have also been 
demonstrated to induce a central response, such as fever (Yirmiya et al., 1996), did not 
produce performance deficits across learning and memory tasks.  Taken together, these 
observation suggests that cognitive dysfunction may not represent as reliable a response 
to infection as it has previously been considered to represent.  Of course, the range of 
doses used in these experiments is not exhaustive, nor have all possible training schedules 
been explored.  Nonetheless, it appears that sickness-induced learning and memory 
deficits, as induced by LPS,- though present- do not generalize to all learning and 
memory tasks that tap hippocampal function.  Nor, it appears, are they peripherally 
mediated by IL-1β. 
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 Cytokines and Long-Term Potentiation in the Freely-Moving Rat (Experiments 8-9) 
Introduction 
     In Experiment 3, animals treated with LPS immediately following conditioning later 
displayed inhibited retention of the original context in which they had been conditioned.  
The following experimental set was done in order to test one central hypothesis on the 
physiological mechanism by which the peripheral immune response, as induced by LPS, 
could impair hippocampal- dependent learning and memory processes.  To date, the most 
viable physiological mechanism underlying hippocampal-dependent learning and 
memory is hippocampal long-term potentiation (LTP).   
     Hippocampal LTP was first discovered in 1973 by Bliss and Lomo who demonstrated 
that high-frequency stimulation of perforant path fibres to the dentate area of the 
hippocampus resulted in a long-lasting increase in the post-synaptic response, as 
evidenced in an increased population postsynaptic excitatory potential (EPSP) and 
population action potential (pop spike).  Because the increase in postsynaptic response 
was limited to the synapses which had been artificially stimulated, Bliss and Lomo 
theorized that this long-lasting potentiation represented a form of synaptic plasticity- 
possibly the form that is required for information storage within the hippocampus (1973).  
In other words, the ability of both human and non-human animals to retain information 
regarding current experience could be partly or wholly dependent upon the ability of the 
synapses within the hippocampus to modify their responses to activation invoked by 
environmental stimuli.  
     Indeed, several experiments conducted since the early 1970s have successfully linked 
hippocampal LTP to learning and memory.  Morris and colleagues (1986) discovered that 
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 the pharmacological blockade of hippocampal LTP induction, via the infusion of a N-
methy-D-aspartate (NMDA) receptor antagonist, produced a selective impairment in 
place learning in animals, an ability previously demonstrated to depend upon the 
hippocampus (O’Keefe, Nadel, Keightley, & Kill, 1975).  In addition, two separate 
research groups demonstrated that spatial learning, another ability dependent upon the 
hippocampus (Morris et al., 1982; Sutherland et al., 1982, 1983), was impaired following 
the artificial in vivo saturation (i.e., blockade) of hippocampal LTP (McNaughton, 
Barnes, Rao, Baldwin, & Rasmussen, 1986; Moser, Krobert, Moser, & Morris, 1998).  It 
was further demonstrated that this spatial impairment disappeared at approximately the 
same rate as it took the saturation of LTP in the dentate gyrus to recover (Castro, Silbert, 
McNaughton, & Barnes, 1989).  Recently, the use of knock-out mice, with a targeted 
gene mutation in the hippocampus causing the delayed clearance of elevated calcium (Ca 
2+) following depolarization, have provided yet another link between hippocampal LTP 
and learning and memory.  These mice show both a lower threshold for LTP induction 
and a corresponding enhancement in performance in several hippocampal learning and 
memory tasks (Jeon et al., 2003) 
     Though substantial evidence indicates that hippocampal LTP processes may be 
necessary to some forms of memory storage (McNaughton et al., 1986; Moser et al., 
1998; Jeon et al., 2003) other studies have demonstrated a dissociation between the 
physiological phenomenon and the cognitive processes it is acclaimed to underlie.  Jo and 
colleagues observed a dissociation between hippocampal LTP and spatial learning:  
Knock-out mice with a targeted gene mutation showed enhanced LTP in the CA1 region 
of the hippocampus as compared to wild-type mice, but both mutant and wild-type mice 
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 performed equally well in the Morris water task (1998).  Other researchers claim that 
spatial impairments, such as those previously observed by Morris et al. (1986), were 
sensori-motor artifacts induced by the NMDA receptor antagonist, and were not selective 
spatial impairments induced by the intended target- the blockade of LTP (Keith & Rudy, 
1990).  In a detailed set of experiments investigating the effects of hippocampal LTP on 
hippocampal learning and memory tasks, Cain and colleagues (1993) demonstrated that 
hippocampal LTP saturation did not adversely affect performance in the Morris water 
task.  In contrast, performance was adversely affected in animals in which hippocampal 
seizures were experimentally induced.  Because the saturation methods used to block 
LTP can also induce hippocampal seizures, this suggests that previously observed 
hippocampal-dependent performance deficits following LTP saturation (McNaughton, et 
al., 1986; Moser, & Morris, 1998; Castro et al., 1989) could have been caused by the 
temporary, seizure-induced perturbation of normal brain function. 
     Though still unresolved and quite controversial, the hippocampal LTP phenomenon 
remains the best candidate for a physiological substrate of learning and memory.  Indeed, 
empirical investigation into cytokine effects on learning and memory have also involved 
cytokine effects on hippocampal LTP. 
     The majority of empirical investigation into cytokine effects on hippocampal LTP 
have been done in vitro.  The consensus of these experiments is that of a robust inhibitory 
effect of both LPS and IL-1β on the induction and /or maintenance of hippocampal LTP.  
The in vitro administration of LPS has been observed to inhibit LTP induction in the CA1 
region of the hippocampus (Jo, Park, Lee, Jung, & Lee, 2001).  Moreover, in vitro 
administration of IL-1β has been observed to inhibit and/or block LTP induction in the 
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 CA1 (Bellinger et al., 1993) CA3 (Katsuki et al., 1990), and dentate gyrus (Cunningham, 
Murray, O’Neill, Lynch, & O’Connor, 1996) regions of the hippocampus, suggesting that 
IL-1β is the mediator of hippocampal LTP inhibition.  
     The only in vivo preparations used to investigate the effects of cytokines on 
hippocampal LTP have been that of the anesthetized animal; however, the inhibitory 
effect of both LPS and IL-1β administration on hippocampal LTP observed in this 
preparation are consistent with the previous in vitro observations. Commins and 
colleagues observed an inhibition in LTP induction in the CA1 region of the 
hippocampus following peripheral LPS administration (2001).  Moreover, Kelly and 
colleagues (2003) observed an inhibition in LTP induction in the dentate gyrus region of 
the hippocampus following i.p. LPS administration.  Similar to the observations made 
using in vitro preparations, the administration of IL-1β appears sufficient to induce this 
impairment.  The intracerebroventricular (i.c.v) administration of IL-1β inhibits 
hippocampal LTP induction (Murray & Lynch, 1998; Vereker, O’Donnell, & Lynch, 
2000).  Results from both in vitro and in vivo anesthetized preparations strongly suggest 
that LPS disrupts hippocampal LTP, and that the pro-inflammatory cytokine, IL-1β, is the 
probable central mediator of this disruption.   
     A later study conducted by Jankowsky and colleagues (2000), however, cast 
considerable doubt on the methods previously used to examine cytokine effects on 
hippocampal LTP.  Because both in vitro recordings and those taken from anesthetized 
animals involve acute tissue damage, which is well-recognized to induce cytokine 
expression, Jankowsky et al. (2000) compared the expression of various cytokines 
following:  hippocampal slice preparation (in vitro), acute electrode implantation in intact 
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 brains (in vivo, anesthetized), and chronic electrode implantation in intact brains (in vivo, 
freely-moving).  They observed that, whereas both the hippocampal slice preparation and 
the acute implantation preparation caused a dramatic increase in a number of different 
cytokines, including IL-1β, the increase returned to basal levels when the animals were 
allowed sufficient time to recover from the surgical procedure, as in the chronic 
implantation preparation.  That is, the chronic in vivo preparation appears to eliminate the 
confounding effects of injury from the study of synaptic activity.  Given this, it appears, 
not only worthwhile, but necessary, to study the effects of LPS and IL-1β on 
hippocampal LTP in the freely-moving animal before drawing any conclusions of a 
cytokine-initiated inhibition of hippocampal LTP. 
     Experiments 8 and 9 were designed to separately assess the effects of peripheral LPS 
and IL-1β on hippocampal LTP in the freely-moving rat.  First, pilot data were collected 
on the effect of successively higher amounts of peripherally-administered LPS, IL-1β, or 
saline on the amplitudes of both the pop spike and EPSP following high-frequency 
stimulation ((HFS) see Appendix C).  From this dose-response curve, the dose of LPS 
and IL-1β that caused the smallest increase in both measures of postsynaptic activity was 
chosen for the following experiments.   
 
Methods 
Drugs  Lipopolysaccharide (LPS Ecoli 026:B6); Sigma, Lot no. 101K4080; 3 million 
endotoxin units per MG) was injected intraperitoneally (i.p.) at a dose of 12 μg/kg.  
Human recombinant interleukin-1beta (hrIL-1β) was purchased from Research 
Diagnostics Inc.((RDI) catalog no. RDI-201b), and injected also at a dose 12 μg/kg . All 
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 saline-treated animals received i.p. injections of an equivalent volume of sterile, pyrogen-
free saline (Abbot Laboratories, Lot no. 79-613-DM-01). 
Procedure 
     Electrode implantation.  Rats were anesthetized with isoflurane and implanted, using 
aseptic surgical techniques, with a single stimulation electrode and a single recording 
electrode.  The recording electrode was implanted in the hilar region of the dentate gyrus  
(Paxinos & Watson coordinates: 3.5 mm posterior to the bregma, 1.8 mm lateral to the 
midline, and 3.6 mm below the top of the skull; see Appendix B for depiction of 
recording electrode trace) and the stimulating electrode was implanted in the ipsilateral 
perforant path (Paxinos & Watson coordinates: 8.1 mm posterior to the bregma, 4.3 mm 
lateral to the midline, and 3.0 mm below the top of the skull). The positions of both depth 
electrodes were optimized under electrophysiological guidance using single pulse 
stimulation (pulse duration = 100 µs, amplitude = 500 µA, frequency = 1 per 30 s).  Two 
stainless-steel, jewelers’ screws were tapped into the skull to serve as reference and 
ground components of the differential recording circuit.  Additional jewelers’ screws 
were tapped into the skull to provide structural support for the electrode assembly, which 
was held in place by dental acrylic cement.  The skin incision was closed with veterinary 
glue and the rats received injections of penicillin G (60,000 I.U. subcutaneous(sc)) and 
buprenorphine (0.05 mg/kg i.p.).  Animals were then individually housed and remained 
unperturbed until electrophysiological recording.  Importantly, though single-housing 
may induce several physiological alterations in the rat (see Plaut & Friedman, 1982 for 
review), it was necessary to individually house the animals post-operatively in order to 
ensure full recovery from the electrode implantation procedure. 
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       Electrophysiology apparatus.  All electrodes were constructed of stainless-steel, 
insulated with teflon, with an outside diameter of 114 µm.  Gold-plated amphenol pins on 
the rat’s head served as connectors to the recording leads. The recording leads passed 
through a commutator and into a differential preamplifier (Grass model P15D) and thence 
to a Neurolog filter and amplifier.  The signal was filtered (1/2 amplitude low frequency - 
1 HZ; 1/2 amplitude high frequency = 10 kHz) and the total amplification was 200X.  
Stimulation was provided by an AMPI Master 8 pulse former and an Isoflex optically 
isolated constant current stimulator.  Signals were displayed on a Nicolet digital storage 
scope, continuously monitored on a Grass audio monitor, and sent to a microcomputer 
running the BrainWave (version 3.3) data acquisition and storage system. The 
Workbench analysis package was used to measure the amplitude of the dentate evoked 
potential.   
     Electrophysiology procedures.  Approximately one week after implantation, daily 
electrophysiological recording sessions began.  Six animals in a within-subjects design 
(six animals per group) were used in Experiments 8 and 9.  An input-output curve was 
produced for each animal, in which the size of the evoked potential was measured at each 
of 6 stimulus pulse intensities (50, 100, 200, 300, 400, 500 µA) - each intensity was 
repeated 10 times at the rate of 1 pulse per 30 s.  To find the optimal baseline intensity for 
each animal, an intensity was chosen which produced a pop spike amplitude that was 
between 50 and 75 percent of the size of the pop spike amplitude generated by the 500 
µA stimulus pulse. This intensity was then used to collect 20 additional evoked 
potentials.  Three continuous days of individual IO curves and baseline recordings were 
taken for each animal.          
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      Following the baseline recording on the third day, animals received one of three 
injections:  12 µg/kg of LPS (Experiment 8), 12 µg/kg of IL-1β (Experiment 9), or an 
equivalent volume of pyrogen-free saline.  For each experiment, the order of injections 
(LPS/ IL-1β or saline) was counterbalanced across animals, and one week passed 
between injections.  One hour following injections, another baseline recording was taken 
in order to determine if the injection procedure or the injected compound itself produced 
any changes in the evoked field potential.  Immediately following the post-injection 
recording, animals received tetanic stimulation at the stimulation site, which consisted of 
10 trains of 10 pulses (frequency = 400 Hz, intensity = 500 µA), with 30 s between each 
train.  Stimulation parameters were then returned to the baseline values and three 
additional recordings were taken:  immediately after high-frequency stimulation, or HFS; 
75 minutes following HFS, and 24 hours following HFS.   
     Two measures were taken of each evoked potential: the slope of the field EPSP 
(EPSP), measured at approximately the middle of the rising slope at a fixed time after the 
stimulus artifact and the amplitude of the trough (population spike (pop spike)) using the 
tangent method (voltage difference between a tangent to the two positive peaks and the 
trough of the negative-going wave component).  
An example of a hippocampal evoked potential is provided in Figure 18. 
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        Figure 18.   Sample hippocampal evoked potential.  The amplitude of an evoked  potential is   
          assessed by the size of the slope of its EPSP and amplitude of its pop spike  
 
     Changes in the evoked responses were expressed as fractional changes from the 
original values measured at the pre-injection baseline.  Animals who did not show a 
greater than or equal to 50 percent increase (.5 AFC) in the pop spike amplitude and a 
greater than or equal to 10 percent increase (.10 AFC) in the EPSP at any of the three 
time points following HFS (immediately following HFS, 75 minutes, 24 hours) were 
considered not capable of showing LTP and were eliminated from the final analyses (not 
all animals show an enhanced synaptic response to high-frequency stimulation (Bliss & 
Lomo, 1973)).  Animals that did not exhibit a measurable population spike and/or EPSP 
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 were also excluded from the final analysis.  To address the possibility that excluded 
animals might have different evoked potentials compared to animals who did not meet 
the above criteria, additional analyses were done on all animals, regardless of the 
response of their evoked potential to high-frequency stimulation.   
Results 
 
Experiment 8  Hippocampal LTP in the freely-moving rat is sensitive to the peripheral 
immune response, as it is invoked by the peripheral administration of LPS.  A paired-
samples t-test performed on the difference between the average fractional change (AFC) 
in the EPSP between LPS and saline-treated animals at each of the three time points 
following HFS revealed a significant difference between groups at 24 hours (t(3) = 5.82, 
p < .01).  However, this effect was not evident at 75 minutes (t(3) = 1.5, p > .05) or 
immediately after (t(3) = 1.4, p > .05) HFS (see Figure 19).  In addition, no differences 
were observed in the EPSP of LPS and saline-treated animals following injection (t(3) = 
1.39, p > .05).  A similar trend was observed when all animals were included in the 
analysis, regardless of the size of the EPSP response to high-frequency stimulation (post-
injection: t(5) = 1.79, p > .05; HFS: t(5) = 1.50, p > .05; 75 min.: t(5) = 2.16, p > .05; 24 
hrs.: t(5) = 4.14, p < .01).  Figures 20 and 21 depict sample evoked potentials from a 
saline-and-LPS-injected animal.  The saline-injected animal (Figure 20) shows a larger-
than-baseline EPSP 24 hours after HFS, whereas the LPS-injected animal (Figure 21) 
shows a smaller-than-baseline EPSP 24 hours after HFS.   
     No differences were observed in the AFC of the pop spike amplitude between groups 
at any of three time points (HFS:  t(4) = -.64, p > .05; 75 min.: t (4) = -.70, p > .05; 24 
hrs.:  t(4) = -.41, p > .05 (see Figure 22)).  In addition, no differences were observed in 
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 the population spike in LPS and saline-treated animals after the injection (t(4) = -1.0, p > 
.05).  Similarly, no between groups differences were observed in the population spoke 
when all animals were included in the analysis, regardless of the response of the 
population spike to high-frequency stimulation (post-injection: t(5) = -1.22, p  > .05 ; 
HFS: t(5) = .10, p > .05; 75 min.: t (5) = .67, p > .05; 24 hrs.: t(5) = .47, p > .05). 
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 Figure 19.  LPS effects on the EPSP of the evoked potential following HFS.  The mean and SEM of the average fractional change 
(AFC) of the EPSP are depicted for animals injected with 12 μg/kg of LPS or an equi-volume amount of sterile pyrogen-free saline.  * 
=  significant difference between groups (p < .05) 
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           Figures 20.   Sample evoked potential from a saline-treated rat.  Twenty-four hours after HFS, this animal shows a  
           potentiated EPSP (i.e., greater slope) in response to baseline stimulus parameters (( “Box” = EPSP slope);  the  
          decline in pop spike  amplitude at 24 hours was not consistently observed across rats)).    
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            Figures 21.   Sample evoked potential from a LPS-treated rat.  Twenty-four hours after HFS, this animal shows  
           a smaller EPSP in response to baseline stimulus parameters and no change in pop spike ( “Box” = slope of EPSP). 
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Figure 22.  LPS effects on the pop spike amplitude of the evoked potential following HFS.  The means and SEMs of the average 
fractional change (AFC) of the pop spike amplitude are depicted for animals injected with 12 μg/kg of LPS or an equi-volume amount 
of sterile pyrogen-free saline.  No significant differences observed between groups (p > .05). 
 
Experiment 9  No significant differences were observed between IL-1β and saline-treated 
animals in the evoked field potential following HFS.  IL-1β-treated animals showed no 
significant difference in the AFC of their EPSP compared to the saline-treated controls, 
neither immediately following (t(3) = -.15, p > .05), 75 minutes (t(3) = -1.46  , p > .05), 
nor 24 hours following (t(3) = 1.83, p > .05) HFS (see Figure 23).  Furthermore, no 
significant differences were observed between groups in the EPSP following injection 
(t(3) = .38, p > .05).  Similarly, no significant differences were observed between groups 
when all animals were included in the analysis, regardless of the EPSP response to high-
frequency stimulation (post injection: t(5) = .27, p > .05; HFS: t(5) = .08, p > .05; 75 
mins.: t(5) = -.77; p > .05; 24 hrs.: t(5) = 1.45; p > .05).   
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      No significant differences were observed between IL-1β and saline-treated animals in 
the AFC of their pop spike amplitude compared to the saline-treated controls, neither 
immediately following (t(5) = 1.38, p > .05), 75 minutes (t(5) = .05, p > .05), nor 24 hours 
following ((t(5) = 1.21, p > .05) HFS (see Figure 24)).  Also, no differences were observed 
between groups in the population spike following injection (t(5) = -.87, p > .05). 
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Figure 23.  IL-1β effects on the EPSP of the evoked potential following HFS.  The mean  and SEM of the average fractional change 
(AFC) of the EPSP are depicted for animals injected with 12 μg/kg of IL-1β or an equi-volume amount of sterile pyrogen-free saline.  No 
significant differences observed between groups (p > .05). 
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Figure 24.  IL-1β effects on the pop spike amplitude of the evoked potential following HFS.  The mean and SEM of the average 
fractional change (AFC) of the pop spike amplitude are depicted for animals injected with 12 μg/kg of IL-1β or an equi-volume amount 
of sterile pyrogen-free saline.  No significant differences observed between groups (p > .05). 
 
 
 
 
Conclusions:  Experiments 8 & 9 
 
     The peripheral immune response, as elicited by the peripheral administration of LPS, 
significantly inhibits the EPSP 24 hours following HFS.  This is the first demonstration 
that hippocampal LTP is sensitive to the peripheral administration of endotoxin in the 
freely-moving rat.  This is significant because the chronic implantation preparation 
allows for testing electrophysiological effects after cytokine activation produced by tissue 
damage has subsided.  Earlier work using in vitro hippocampal slice preparations and in 
vivo acute recording preparations are confounded by the release of endogenous cytokines, 
as demonstrated by Jankowsky and colleagues (2000).  It appears that hippocampal  
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 synaptic plasticity is disrupted by the induction of the peripheral immune response. The 
mechanism by which LPS affects EPSP slope may be through an NMDA-inhibitory 
effect.   Jo et al. (2001) work in patch-clamp recording revealed that LPS inhibits the 
EPSP specifically by blocking calcium (Ca 2+) entry through post-synaptic NMDA 
receptors. 
     The present demonstration that the EPSP is inhibited by the peripheral administration 
of LPS is consistent with Vereker et al.’s observation that, in the anesthetized animal, the 
peripheral administration of LPS significantly inhibits the EPSP (2000). However, unlike 
Verker et al. who observed an inhibition in the persistent rise in the EPSP over a forty- 
minute period following HFS (2000), LPS was not observed to significantly inhibit the 
EPSP immediately following, nor 75 minutes following HFS.  This difference may be 
ascribed to inherent differences involved in acute and chronic in vivo preparations.  Rick 
and Milgram (1999) observed that, in acute, anesthetized preparations, the continuous 
application of moderate-intensity stimulation pulses (not HFS) induced increases in both 
the population spike amplitude and EPSP slope, while chronically-implanted freely-
moving animals showed significant increases in the pop spike amplitude, but significant 
decreases in the EPSP slope.  If the EPSP slope is already inhibited to a certain degree in 
the freely- moving animal, then it is conceivable that it would not be as sensitive (i.e, 
“not as much size to lose”) to the administration of LPS as it would be in an anesthetized 
animal. 
     No significant differences were observed in the evoked potential in IL-1β-treated 
animals.  This observation contrasts previous observations that IL-1β inhibits LTP in the 
hippocampus in vitro (Bellinger et al., 1993;  Katsuki et al., 1990; Cunningham et al., 
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 1996), or that the central administration of IL-1β inhibits hippocampal LTP in the 
anesthetized animal (Vereker et al., 2000; Murray & Lynch, 1998).  Experiment 9 was 
the first experiment to test the effects of IL-1β on hippocampal LTP in the freely-moving 
animal.  Moreover, Experiment 9 was the first experiment to test the effects of 
peripherally-administered IL-1β on hippocampal LTP.  The observation, then, that the 
peripheral administration of IL-1β has no effects on the evoked potential following HFS 
could be attributed to either the absence of an effect of peripheral IL-1β on hippocampal 
synaptic plasticity, or an absence of an effect of IL-1β,- be it peripheral or central,- on 
hippocampal syntaptic plasticity in the freely-moving animal.  Certainly, additional 
studies are needed to separate the effects of central administration of IL-1β from 
peripheral administration of IL-1β on hippocampal LTP in the freely-moving rat.  
Nonetheless, the observation that peripheral administration of IL-1β has no effect on 
hippocampal LTP in the freely-moving rat strongly supports the argument that the 
peripheral actions of the pro-inflammatory cytokine, IL-1β, do not have a primary 
peripheral signaling role in the disruption of hippocampal LTP.  The peripheral 
administration of IL-1β does cause a similar, albeit non-significant, trend in the EPSP as 
compared to the LPS-treated animals (see Figure 21).  It may be the case that, in addition 
to IL-1β, the actions of other proinflammatory cytokines are required in the periphery to 
disrupt hippocampal LTP. 
     Of additional interest is the observation that saline-treated animals in experiments 8 
and 9 had an EPSP below–baseline-value at 75 minutes (and at 24 hours in Experiment 
9).  To explore the possibility that experimental handling, necessary to the connection of 
the animal to the recording apparatus, confounded the change in the EPSP following 
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 HFS, evoked potentials following HFS were continuously recorded from an unperturbed 
animal for two hours following HFS, and then at 24 hours after HFS (see Appendix D).  
The change in the EPSP over the two- hour period mirrored that of the majority of 
animals in the experiments.  That is, the initial rise in the AFC of the EPSP following 
HFS slowly diminished over the course of one hour until it fell below baseline values.  It 
then returned to higher-than-baseline values at 24 hours.  Reasonably, the depressed 
EPSP observed at 75 minutes in the control animals was not an artifact of experimental 
handling, but rather could be a result of differences in the animals’ body core 
temperatures as a function of activity state.   
     While measuring temperature change following different injections (see Appendix A), 
it was observed that the saline-treated animal’s temperature steadily decreased as it fell 
asleep (activity state was observed by experimenter and not systematically recorded).  
Cain and colleagues (1994) observed that the evoked field potential in the dentate gyrus, 
by stimulation of the perforant path, varied with both behaviour and brain temperature.  
Specifically, they observed that slow-wave sleep correlated with a decreased field EPSP 
slope and an increased population spike amplitude. It could reasonably be inferred, 
therefore, that the animals who showed inhibited EPSPs at 75 minutes were in slow-wave 
sleep.  If animals’ temperatures were experimentally controlled, either by increasing the 
ambient temperature in the testing room to over-ride sleep-induced hypothermia or by 
artificially maintaining the animals in a state of constant activity, then it is suspected that 
the decrease in the EPSP slope, as observed in the present experiments at the 75 minute 
time point, would be abolished.  Additional studies are required to test this hypothesis.  
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      If the argument is followed, then, that slow-wave sleep inhibits the EPSP slope, it is 
possible that the inhibited EPSP slope observed in the LPS-treated animals could be an 
indirect effect of an LPS-induced increase in slow-wave sleep, rather than a direct LPS-
induced inhibitory effect on hippocampal synaptic plasticity.  Though the febrile effects 
of LPS have been observed to dissipate after 8 hours (Yirmiya, Tio, & Taylor, 1996), 
results from Experiment 2 suggests that LPS-induced reductions in general motor activity 
persist for as along as 24 hours.  Additional studies of LPS and hippocampal LTP require 
the separate assessment of LPS-induced soporific effects from LPS-induced inhibitory 
effects on hippocampal physiology.  
     In summary, data from Experiment 8 demonstrate for the first time that hippocampal 
LTP in the freely-moving animal is disrupted by peripheral LPS administration.  The idea 
that this disruption might be an indirect result of the sedative consequences of infection is 
an intriguing one and warrants further investigation.  No differences were observed in the 
pop spike amplitude in the LPS - treated animals compared to controls.  However, this 
was not the first observation of a dissociation between the EPSP and the population 
spike, as previous researchers have observed similar dissociations following different 
experimental manipulations, including pharmacological (Munro, Walling, Evans, & 
Harley, 2001) and dietary (Bronzino, Austin-Lafrance, Mokler, & Morgane, 1997) 
manipulations.  Notably, some researchers (Verker et al., 2000) measure just the EPSP as 
an assessment of hippocampal LTP.  Though the functional consequence of an inhibited 
EPSP, yet normal pop spike, remains to be elucidated, the LPS-induced EPSP inhibition 
observed in Experiment 8 is consistent with the LPS-induced disruption of memory 
consolidation observed in Experiment 3, suggesting that sickness-induced disruption of 
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 memory consolidation may have a physiological basis in disrupted hippocampal synaptic 
plasticity. 
     Data from Experiment 9 demonstrate that IL-1β it not the primary peripheral signaling 
molecule linking peripheral inflammation to disruption of hippocampal synaptic 
plasticity.  The observation of a trend (non-significant) for a lower 24-hour EPSP in the 
IL-1β-treated animals that is similar to the inhibition (significant) in the 24-hour EPSP 
observed in the LPS-treated animals, suggests that additional proinflammatory molecules 
are required to induce a statistically-reliable EPSP inhibition.  This observation is 
consistent with the observation from Experiment 4 that a similar dose of IL-1β caused a 
non-significant, inhibitory trend in context retention similar to that of LPS.  Notably, the 
dose of IL-1β that was used in Experiments 1 and 2 to produce reliable changes in food 
consumption, body weight, and general motor activity was insufficient in the present 
experiment to reliably disrupt hippocampal LTP.  This observation suggests that 
cognitive dysfunction, though it has demonstrated behavioural (Experiment 3) and 
physiological correlates (Experiment 8), does not appear to share similar signaling 
molecules (i.e., IL-1β) as other sickness behaviours, nor does it appear to be as central of 
a component of the sickness response as other sickness behaviours. 
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 Cytokines and Hippocampal Cell Proliferation 
 
Introduction 
 
 
     Results from Experiment 8 support an LPS-induced inhibition of long-term 
potentiation in the freely-moving rat.  The absence of a significant effect, but presence of 
an IL-1β-induced inhibitory influence on hippocampal LTP, suggests that IL-1β, alone, is 
not sufficient to reliably inhibit hippocampal LTP in the freely- moving rat.  Rather, it 
appears that additional proinflammatory cytokines are required in the periphery to induce 
a statistically reliable inhibitory effect on hippocampal physiology. 
Interleukin-6   Interleukin-6 (IL-6) is a proinflammatory cytokine that likely plays a role 
in peripheral inflammation-induced hippocampal inhibition.  There is anatomical and 
functional evidence, coupled with theoretical reason, to believe that IL-6 is necessary to 
inducing an inhibitory effect on hippocampal physiology.  First, IL-6 and IL-6 receptor 
(IL-6R) mRNA has been localized in the pyramidal and granular neurons of the 
hippocampus (Schobitz, Voorhuis, & de Kloet, 1992; Schobitz, de Kloet, Sutanto, & 
Holsboer, 1993).  Second, peripheral exposure to endotoxin stimulates the biosynthesis of 
IL-6R within the hippocampus (Vaillieres & Rivest, 1997), indicative that the peripheral 
inflammatory response induces the central hippocampal expression of IL-6.   
     The theoretical reason for suspecting IL-6 has a role in the inhibition of hippocampal 
function is not based on empirical results, but is none-the-less compelling.  As described 
previously, the term sickness behaviour emerged as a term that comprised those 
behaviours- eating, drinking, socializing, learning- that are compromised in times of 
illness, in order to save the additional metabolic energy required to mount the febrile 
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 response necessary to pathogen clearance (Kluger, 1992).  In other words, sickness-
induced cognitive dysfunction is organized around,- or occurs in order to accommodate,- 
the febrile response.  Experimental manipulations, then, that result in the greatest febrile 
response, should also cause greater inhibitions of hippocampal physiology and function. 
     A series of experiments conducted by Cartmell and colleagues (2000) demonstrated 
that, though the administration of peripheral IL-1β alone was sufficient to induce a fever 
(IL-1β is an endogenous pyrogen as well as an inducer of IL-6 production), the peripheral 
co-administration of IL-1β with IL-6 produced a fever of greater magnitude and of 
greater duration than that which developed from the peripheral administration of either 
cytokine alone.  Moreover, animals pre-treated intraperitoneally with IL-6 antiserum 
failed to show a febrile response to the peripheral administration of LPS.  From these 
data, the authors conclude that IL-6 acts in concert with IL-1β at the local site of 
peripheral inflammation before entering the circulation.  Once it enters the circulation, 
the authors conclude that IL-6 activates central nervous system mechanisms to produce a 
febrile response during illness.  Because the peripheral administration of IL-6 augments 
one of the central responses to illness, it follows that the peripheral administration of IL-6 
might indeed augment other central responses to illness, including the inhibition of 
learning and memory, and possibly, hippocampal functioning.   
Hippocampal Cell Proliferation  Experiment 10 was done to determine if IL-1β, when co-
administered with IL-6, would inhibit hippocampal cell proliferation.  This study is 
necessary to the investigation of cytokine effects on cognition for two reasons.   First, the 
quantification of hippocampal cell proliferation is an indirect assessment of hippocampal 
neurogenesis, a cellular process that has been observed to represent a correlate of learning 
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 and memory, and, more specifically, to memory consolidation (Feng et al., 2001; 
Kempermann, 2002 (review)). 
     Similar to hippocampal LTP, hippocampal neurogenesis proves attractive as a 
physiological counterpart to learning and memory because it can be up-or down-
regulated following different experiences (see Kempermann, 2002 for review).  Perhaps 
the most compelling argument for a role of neurogenesis in learning and memory comes 
from Feng and colleagues (2001) who show that transgenic mice lacking a gene 
necessary to post-learning enrichment neurogenesis display a normal fear response to the 
auditory cue in the contextual fear conditioning paradigm, but show a heightened fear 
response to the context compared to control animals.  Importantly, the transgenic animals 
who were exposed to an enriched environment prior to conditioning showed a level of 
retention similar to enriched non-transgenic animals.  From these data, the authors argue 
that, rather than being necessary to the formation of new memories, neurogenesis is 
necessary to memory consolidation.  That is, the authors argue that hippocampal 
neurogenesis aids memory consolidation by degrading temporarily stored memory traces 
in the hippocampus once extra-hippocampal memory consolidation has taken place.  If 
these memory traces are not cleared from the hippocampus, the authors argue that the 
hippocampus becomes overloaded and unable from acquiring and processing new 
memories (Feng et al., 2001).  Therefore, it is possible that dysregulation of hippocampal 
neurogenesis may be a correlate of memory consolidation dysregulation, such as that 
which was observed by Pugh and colleagues (1998) and replicated in Experiment 3.  In 
the least, hippocampal neurogenesis is a correlate of hippocampal physiology, and its 
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 investigation will provide insight as to whether cytokines act on a physiological level to 
disrupt learning and memory.  
Hypothesis  This experiment is designed to assess whether  the peripheral administration 
of two proinflammatory cytokines,- IL-1β and IL-6,- will have an inhibitory effect on  
hippocampal cell proliferation.  Because this experiment was designed to assess the 
short-term (i.e., few hours) effects of an acute injection of IL-1β and IL-6 on 
hippocampal physiology, animals were perfused the same day as injections.  Presumably, 
animals that show less hippocampal cell proliferation should also show less hippocampal 
neurogenesis.  If illness-induced cognitive dysfunction arises from a direct, inhibitory 
effect of proinflammatory cytokines on hippocampal physiology, then reduced cell 
proliferation should be observed in animals pre-treated with IL-1β and IL-6.  In contrast, 
if illness-induced cognitive dysfunction arises from an indirect effect of cytokines on an 
extra-hippocampal system, then no differences in cell proliferation should be observed 
between cytokine and saline-treated animals. 
     Quantification of cell proliferation.  To quantify the genesis of new cells in the dentate 
gyrus, BrdU labeling will be used.  5-Bromo-2’-Deoxyuridine (BrdU) is a thymidine 
analog that is incorporated into the DNA of dividing cells (Miller & Nowakowski, 1988) 
and is considered a marker for cell genesis.  BrdU can be visualized with 
immunhistochemical techniques and quantitatively assessed with stereological counting 
techniques.  Thus, in the following experiment, hippocampal cell proliferation is assessed 
as the number of cells that are labeled with BrdU. 
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Methods 
Procedure   
     Drugs.  Cytokine-treated animals (n = 5) received a 20 μg/kg injection of recombinant 
human interleukin-6 ((rhIL-6), PeproTech Inc., Canada, catalog no. 200-06, lot no. 
02016)), followed one hour later by an .2 μg/kg injection of recombinant human 
interleukin-1β ((rhIL-1β), PeproTech Inc., Canada, catalog no. 200-01B, lot no. 037951).  
The doses, timing, and order of the injections were chosen to maximize the febrile 
response that had previously been observed by Cartmell and colleagues (2000).  Saline-
treated animals (n = 5) received equivalent volumes of pyrogen-free saline (Abbot 
Laboratories, Lot no. 79-613-DM-01).  One hour following the last IL-1β injection, all 
animals received an injection of 150 mg/kg of BrdU  (Sigma Aldrich; lot no. 71K1172).    
     Tissue processing.  Three hours following BrdU injections, all animals were perfused 
transcardially with phosphate buffered saline (PBS) followed by Lanas fix 
(paraformaldehyde (PFA), phosphate buffer (PB), picric acid (PA)). All brains were 
removed and post-fixed in individual containers with Lanas fix and stored at 4° C.  Using 
a vibratome, serial sections of the brains were cut through the hippocampus (plates 26-40; 
Paxinos and Watson, 1998) in 50 μm sections into 0.1 M PBS.  Tissue was collected in 
microcentrifuge tubes filled with PB and stored at 4° C until processed for 
immunohistochemistry. 
     Immunohistochemistry.  Every fifth section of the hippocampus was processed for 
BrdU.  For BrdU immunohistochemistry, free-floating tissue sections were incubated in 
2N HCL for 30 minutes at 50° C.  After being washed in PB, sections were incubated in 
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 rat anti-BrdU (Accurate, 1:175), goat serum (3 drops/5 ml), and 3% Triton-X (1:20) 
overnight at 4° C.  Sections were then washed in PB and incubated overnight at 4° C in 
goat anti-rat solution (Chemicon, 1:1000).  After another wash with PB, sections were 
treated overnight with anti-mouse Alex-4888-conjugated secondary antibodies 
(Molecular Probes, 1:500 in PBS), washed in PB, and incubated overnight in Streptavidin 
568-conjugated secondary antibodies.  Sections were then washed a final time with PB, 
mounted onto 1% gel slides and cover-slipped with anti-fading mountant. 
     Unbiased stereology.  The stereological technique used to quantify the number of 
BrdU-labeled cells was based on the optical fractionator method described by West 
(1993).  A randomly selected serial series comprised of every fifth 50 μm section through 
the hippocampus was analyzed from each animal.  A Zeiss LSM 410 Laser fluorescent 
microscope was used to z-section images at 1 μm intervals.  Z-sectioning was controlled 
by Zeiss LSM 5 image browser software.  All BrdU- 
labeled cells within the hilus, subgranular zone, and the granular cell layer of the dentate 
gyrus were counted.  Four sides (eight sections) were counted from each animal.  To 
estimate the total number of BrdU-positive cells within the hippocampus, an average of 
the total number of BrdU-positive cells was calculated for each section and multiplied by 
five.  
Results 
     As depicted in Figure 25, more BrdU-positive cells were observed in the dentate gyrus 
of saline-treated animals compared to cytokine-treated animals (t(7) = 8.46; p< .001; 
refer to Figure 26 to view immunhistochemical stain of BrdU-labeling). 
. 
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              Figure 25.  Effects of cytokines on dentate gyrus cell proliferation.  Mean and the SEM of the estimated number              
                 of  BrdU-positive cells are depicted for animals treated with 20μg/kg of IL-6 + .2μg/kg of IL-1β or an equi- 
                 volume amount  of pyrogen-free saline.  *** Significant difference observed between groups ((p < .001);  
                 statistical analysis performed on raw data;  one animal from cytokine-treated group excluded from analysis due  
                  to a poor perfusion). 
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 Conclusions:  Experiment 10 
     The peripheral administration of the proinflammatory cytokines IL-1β and IL-6 cause 
significant reductions in hippocampal cell proliferation.  This is the first experiment to 
show significant reductions in hippocampal cell proliferation resulting from the 
peripheral administration of proinflammatory cytokines.  These results suggest that the 
acute administration of the proinflammatory cytokines IL-1β and IL-6 induce a relatively 
rapid (i.e., less than 4-5 hrs) suppression of hippocampal cell proliferation.  These data 
are consistent with  a previous observation that the peripheral inflammatory response, 
induced by the peripheral administration of LPS, causes reduced hippocampal 
neurogenesis (Monje, Toda, & Palmer, 2003).  In addition, Vaillères and colleagues 
(2002) observed reduced hippocampal neurogenesis in adult transgenic mice with chronic 
astrocytic productic of IL-6, suggesting that chronic, in addition to the acute, 
administration of IL-6 reduces hippocampal neurogenesis.   
     One limitation of the use of BrdU-labeling method to quantify hippocampal cell 
proliferation is the difficulty in assessing whether the experimental treatment caused 
changes in cell proliferation per se, or whether the experimental treatment caused 
changes in blood-brain-barrier permeability which, in turn, caused altered labeling 
patterns across groups.  Though possible, it is unlikely that altered blood-brain barrier 
permeability in the cytokine-treated group caused the direction of results that were 
observed in the present experiment.  Though no study has investigated the effects of an 
acute peripheral injection of IL-1β and / or IL-6 on blood-brain barrier permeability, 
available data suggest that the peripheral inflammatory response increases blood-brain 
barrier permeability (Mark & Miller, 1999; Arsenijevic et al., 2000; Stanimirovic & 
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 Satoh, 2000 (review)).  It is reasonable to conclude, therefore, that if altered blood-brain 
barrier permeability caused differential labeling across groups, then this effect would 
have been observed in the opposite direction (i.e., cytokine-treated group would show 
greater hippocampal cell proliferation).  Because an effect in the opposite direction was 
not observed, cytokines most likely act by directly inhibiting hippocampal cell 
proliferation.  
     In addition, though the intent of this present experiment was to assess the short-term 
effects of an acute proinflammatory injection on hippocampal physiology, it cannot be 
concluded with certainty that the cytokine-treated animals would also show reduced 
neurogenesis had they been injected with BrdU for several days.  Though implausible, it 
is possible that a greater percentage of the newly-generated cells in the cytokine-treated 
group compared to the saline-treated group would differentiate into new neurons.  Again, 
though no data are available to support this scenario, additional experiments should 
investigate the effects of an acute injection of proinflammatory cytokines on hippcampal 
neurogenesis. 
     The observation that the peripheral administration of IL-1β and IL-6 causes reduced 
hippocampal cell proliferation has several implications.  First, because it can be inferred 
that reduced hippocampal cell proliferation correlates with reduced hippocampal 
neurogenesis (with the above caveats in mind), and because hippocampal neurogenesis 
has been empirically linked to memory consolidation (Feng et al., 2001), it is possible 
that the LPS-induced impairment in post-trial memory consolidation observed by Pugh 
and colleagues (1998), and replicated in Experiment 3, is a behavioural correlate of 
inhibited hippocampal physiology.  
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      Secondly, the observation that peripheral cytokine administration has a direct 
inhibitory effect on a hippocampal process supports the observation in Experiment 8 of a 
LPS-induced inhibitory effect on hippocampal LTP.  Though the possibility of an indirect 
suppression of hippocampal LTP via a LPS-induced enhancement of slow-wave sleep 
remains, the data from this experiment make a stronger case for a direct, cytokine-
induced inhibitory effect on hippocampal physiology.  
     Finally, the data from this experiment highlight the importance of IL-6 as a potential 
peripheral mediator of hippocampal inhibition and consequent cognitive dysfunction.  
Though additional experiments are required to separately assess the effects of IL-6 from 
IL-1β on hippocampal neurogenesis, peripheral IL-6 may play more of a role in sickness-
induced cognitive dysfunction than has previously been considered, and possibly, more 
of a peripheral role than the much-maligned IL-1β.  
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 General Conclusions 
Re-statement of current theory 
     The experiments included in this dissertation were completed to determine whether 
the proinflammatory cytokine IL-1β is the major peripheral mediator of sickness-induced 
cognitive dysfunction, as well as to characterize the components and underlying 
mechanisms of sickness-induced cognitive dysfunction.  To re-state the current generally 
accepted theory in this field:  Cognitive dysfunction is one of several behavioural 
consequences of the peripheral inflammatory response, and represents a principle 
component of the organized behavioural response to peripheral inflammation.  Moreover, 
the potent pro-inflammatory cytokine, IL-1β, is both the primary central and peripheral 
mediator of sickness-induced cognitive dysfunction (Danzer, 2001; Maier, 2003; Maier & 
Watkins, 2003). 
     Though generally accepted, this theory holds little empirical ground.  Certainly, it 
appears to be true that the central release of IL-1β,-  experimentally induced by the i.v. or 
i.c.v administration of IL-1β,- impairs learning and memory across a variety of paradigms 
(Oitzl et al., 1993; Barrientos et al., 2002).  In addition, in vitro (Jo et al., 2001; Bellinger 
et al., 1993; Katsuki et al., 1990; Cunningham et al., 1996), and in vivo studies done in 
the anesthetized animal (Commins et al., 2001; Kelly et al., 2003; Vereker et al., 2000; 
Murray & Lynch, 1998), have suggested hippocampal LTP inhibition as a possible 
mechanism by which the inflammatory response impairs learning and memory.     
     Though tantalizing, experiments such as these do not provide adequate support for the 
argument that it is the peripheral inflammatory response, of which IL-1β has been 
proposed as the principle mediator, that impairs learning and memory.  Of the few 
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 experiments that have investigated the effects of LPS and/or IL-1β on learning and 
memory, the majority have involved central administration (Oitzl et al., 1993; Barrientos 
et al., 2002), while the few that have involved peripheral administration have produced 
weak (Shaw et al., 2001) or mercurial  (Gibertini, 1998) results.  In addition, the timing 
of compound administration relative to training used in these learning and memory 
experiments render it impossible to determine what component of cognition is impaired 
(i.e., acquisition (new learning), consolidation of recent learning, or long-term retention).  
The peripheral administration of LPS and IL-1β, the separate assessment of their effects 
on different cognitive components, and the convergence of evidence across learning and 
memory paradigms are required to establish the characteristics of sickness-induced 
cognitive dysfunction, as well as to determine the peripheral role of IL-1β in the 
induction of cognitive dysfunction. 
     Prior hippocampal LTP work offers only weak support for the current theory.  The in 
vitro (e.g., Jo et al., 2001) and in vivo (e.g., Commins et al., 2001) preparations that were 
used to investigate the effects of LPS and / or IL-1β on hippocampal LTP are confounded 
because of the massive cytokine response to tissue injury (Janowsky et al., 2000).  
Cytokine response to tissue injury aside, no experiments have investigated the effects of 
LPS and/or IL-1β on hippocampal LTP in the awake, freely moving (and freely sleeping) 
rat.  Such experiments are essential to the understanding of whether LPS and/or IL-1β 
have a physiological role in sickness-induced disruption of hippocampal synaptic 
plasticity. 
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 Summary of Experiments 1-10 
      Following the confirmation that peripheral LPS induced a robust and reliable sickness 
response (Experiments 1 and 2), Experiments 3-9 were done in an effort to characterize 
the components of cognition that are impaired by sickness, as well as to determine 
whether or not peripheral IL-1β has a primary, physiological role in triggering sickness-
induced cognitive dysfunction and / or the disruption of hippocampal synaptic plasticity. 
     Before the components and role of peripheral IL-1β in sickness-induced cognitive 
dysfunction could be determined, however, it had to be established whether or not the 
peripheral administration of LPS did, in fact, induce cardinal physiological and 
behavioural signs of sickness, which include:  reduction in general motor activity, 
reduction in food consumption, loss of weight, and a febrile response.  Indeed, in 
Experiments 1 and 2, the peripheral administration of LPS reliably induced all these signs 
of sickness.  Peripheral administration of IL-1β also induced these sickness symptoms.  
Therefore, it can be concluded from Experiments 1 and 2 that the peripheral 
administration of LPS does render an animal ill, and that peripheral IL-1β is sufficient to 
induce several symptoms of illness. 
     So, is the peripheral administration of IL-1β sufficient to induce learning and memory 
deficits?  A wide range of doses were used to test the effects of peripherally-administered 
IL-1β on learning and memory in the contextual fear conditioning task and the Morris 
water task.  Importantly, the doses that were used had previously been demonstrated to 
induce a sickness response (Experiments 1,2; Yirmiya et. al., 1996).  Yet, these doses did 
not produce deficits in performance in Experiments 3-7.  So, these animals were ill, yet 
were able to learn and retain information at a level on par with healthy controls.  
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 Together, these observations demonstrate that peripheral IL-1β is not sufficient to induce 
cognitive dysfunction. 
     So, what cognitive processes,- if any,- are affected by the peripheral inflammatory 
response?   Again using a wide range of doses, performance was measured on a variety of 
learning and memory tasks following peripheral LPS administration.  Evidence already 
existed to suggest that the peripheral administration of LPS would impair memory 
consolidation (Pugh et al., 1998), so an attempt was made to replicate this experiment in 
Experiment 3.  Importantly, animals injected with a low-moderate dose (2 :g/kg) of LPS 
immediately following conditioning did show a significant impairment in context 
retention, as had been previously demonstrated by Pugh and colleagues (1998).  
However, this impairment in post-trial memory consolidation did not generalize to an 
impairment using a consolidation moving-platform version of the Morris water task, 
another hippocampal-sensitive memory task.  The different effects observed across the 
tasks may be due to different task requirements.  For example, the contextual fear 
conditioning task required the animal to rapidly acquire (during the 5 minute conditioning 
period) a configural representation of the environment.  LPS only disrupted the 
consolidation of this representation if the animal had not been previously exposed to the 
environment, implying that LPS only disrupts recently acquired representations (Pugh et 
al., 1998).  In contrast, the Morris water task required that the animal learn the location of 
a recently-moved hidden platform in a room with a stable cue-set. These animals may 
have had already acquired a stable representation of the environment in which they had to 
find the platform, making their representations less sensitive to the disruptive effects of 
LPS.  These animals “only” had to update their representation to include a new platform 
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 location, but they did not have to acquire a completely new configural representation.  
Task differences such as these point to the necessity of testing learning and memory 
across a variety of paradigms.  There is empirical support for an LPS-induced inhibition 
of memory consolidation (Pugh et al., 1998; Experiment 3).  However, it appears that this 
impairment is sensitive to the task (Experiment 4), suggesting that sick animals are able 
to overcome sickness-induced learning and memory impairments under certain 
conditions.  Certainly, it appears then, that the cognitive dysfunction component of the 
constellation of symptoms referred to as sickness behavior is not, necessarily, a principle 
component.  Animals rendered ill by LPS, not only are capable of acquiring and retaining 
information regarding a familiar environment, but they do so quite well. 
     Experiments 8 and 9 were designed to test whether the induction of hippocampal LTP 
would be sensitive to the peripheral immune response in the freely-moving rat, and, if so, 
whether the peripheral administration of IL-1β would be sufficient to disrupt 
hippocampal LTP.  For the first time, it was demonstrated that hippocampal LTP in the 
freely-moving animal is, indeed, disrupted by the peripheral administration of LPS.  
However, no disruption in LTP was observed following the peripheral administration of 
IL-1β.  Consistent with previous observations that peripherally-administered IL-1β has no 
effect on the acquisition, consolidation, or retention of information, it also appears that 
IL-1β has no primary peripheral signaling role in the disruption of hippocampal synaptic 
plasticity.  It is interesting to note, however, that, though not statistically reliable, the 
peripheral administration of IL-1β causes a similar downward shift in the EPSP at 24 
hours following injection, similar to the peripheral administration of LPS.  It is possible, 
therefore, that peripheral IL-1β has a role in the disruption of hippocampal synaptic 
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 plasticity, but that the actions of additional proinflammatory cytokines are required in the 
periphery to reliably disrupt synaptic plasticity. 
     As observed in Experiment 10, the combined administration of IL-6 and IL-1β 
significantly inhibited hippocampal cell proliferation, suggesting, in part, that IL-6 may 
have an important peripheral role in hippocampal modulation of learning and memory. 
     In conclusion, the results of the present series of experiments do not support the 
current theory regarding peripheral IL-1β and sickness-induced cognitive dysfunction.  
Data from the present series of experiments confirm: 1)  Sick 
 (i.e., febrile) animals share several behaviours, including reductions in food 
consumption, body weight, and general motor activity; 2)  Sick animals show some 
cognitive dysfunction;  3)  Sickness-induced cognitive dysfunction may have a cellular 
basis in the disruption of hippocampal LTP; and 4)  Peripheral IL-1β is sufficient to 
induce some sickness behaviours (e.g., anorexia, lethargy).   
     However, the same data do not confirm that peripheral IL-1β is sufficient to induce 
learning and memory impairments or to reliably disrupt hippocampal LTP.  If a 
peripheral role exists for IL-1β in sickness-induced cognitive dysfunction, then it must 
work in concert with other proinflammatory cytokines .  Additionally, the data do not 
confirm that cognitive dysfunction represents an integral component of the sickness 
response.  Rather, the data support the idea of a sickness-induced impairment in the 
consolidation of recent learning that is sensitive to the requirements of the task-at-hand.  
Furthermore, the observation of a cytokine-induced disruption in hippocampal LTP and 
hippocampal cell proliferation supports a cellular basis for sickness-induced learning and 
memory impairments.  
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 Future research 
     When the proinflammatory cytokines were first experimentally linked to sickness 
behaviour, interest grew in the proinflammatory cytokines as potential psychotherapeutic 
targets (e.g., Reichenberg et al., 2001; Kent et al., 1992).  The idea of proinflammatory 
cytokine antagonists as therapeutic agents was, not only a novel concept, but an 
extremely attractive one, as the proinflammatory cytokines were believed to underlie the 
neurological impairments common to: acute infection (Reichenberg et al., 2001), HIV 
infection (Wesselingh & Thompson, 2001); systemic lupus erythematosus (Lauwerys & 
Houssiau, 2003); and aging (Wilson et al., 2002).  Also, anti-cytokine therapy had 
already been demonstrated to successfully treat several pathologies with a large 
inflammation component, such as SLE, heart disease, and inflammatory bowel disease 
(Yokota, 2003 (review); Ito, 2003 (review); Ogata & Hibi, 2003 (review); & Diwan, et 
al., 2003 (review)).  It was, - and is,- highly conceivable that anti-cytokine therapy could 
be used to treat the cognitive dysfunction that accompanies other pathologies marked by 
aberrant immune activation.   
     However, it appears that in the race of drug discovery, two key elements have been 
left by the road side.  First, cognitive dysfunction may not constitute as primary a role in 
sickness behaviour as had first been suggested.  Certainly, data from Experiments 3-7 
suggest that sick animals show some cognitive impairments, but the same data also 
suggest that this impairment is acutely sensitive to LPS dose and task requirements.  This 
is not the case with other behavioural and physiological symptoms of sickness.  The 
animals in Experiments 1 and 2 displayed several symptoms of sickness, such as reduced 
food consumption and consequent weight loss, across a range of doses and task 
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 conditions.  It appears from these observations, then, that the physiological mechanisms 
underlying sickness-induced cognitive dysfunction are functionally discrete from those 
underlying other sickness behaviours, and, as a consequence, should be put under a 
different “microscopic lens” in empirical investigation. 
     The second key element that has not been suitably addressed in the drug discovery 
effort is that of fundamental differences between the central and peripheral inflammatory 
response.  As previously discussed, evidence exists to strongly suggest that the 
proinflammatory cytokine, IL-1β, has a fundamental and primary role in cognitive 
dysfunction resulting from a central inflammatory response (Oitzl et al., Barrientos et al., 
2002).  However, there is a glaring lack of evidence that the same can be said for 
cognitive dysfunction resulting from a peripheral inflammatory response.  Experiments 
3-9 do not support a role for peripheral IL-1β in cognitive dysfunction across a range of 
doses, nor across different learning and memory tasks.  If proinflammatory cytokine 
antagonists are going to be used to treat inflammation-induced cognitive dysfunction in a 
human population- be it in the form of a bolus injection or a continuous infusion- they are 
going to be administered peripherally.  Moreover, the discovery of anti-cytokine therapy 
that targets a single proinflammatory cytokine is preferable to one that induces a general 
immune suppression, as the non-specific effects of immunosuppressive drugs have been 
demonstrated to be greatly reduced by using cytokine-specific inhibitors (Weckmann & 
Alcocer-Varela, 1996).  It is for these reason that empirical investigation into cytokine-
induced cognitive dysfunction needs to be re-directed to the peripheral inflammatory 
response, as well as to other proinflammatory cytokines. 
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      Data from the present series of ten experiments suggest the direction in which 
empirical investigation into the cytokine-cognitive dysfunction relationship should 
proceed.  First, because IL-1β does not appear to be the primary peripheral mediator of 
sickness-induced cognitive dysfunction, the effects of other proinflammatory cytokines 
on learning and memory should be investigated.  The observation that the peripheral 
administration of IL-6 inhibits hippocampal cell proliferation suggests that peripheral IL-
6 may have an important role in hippocampal learning and memory systems.   
     Another proinflammatory cytokine that warrants investigation is tumor necrosis 
factor- alpha (tnf-α).  Following peripheral LPS administration, tnf-α has been observed 
to be up-regulated in the hippocampus to a higher degree than  
 IL-1β (Sunter et al., Society for Neuroscience, 2003).  Also, in addition to having higher 
plasma levels than IL-1β following i.p. LPS administration, both IL-6 and tnf-α are up-
regulated in the paraventricular nucleus (PVN) of the hypothalamus to a higher degree 
than IL-1β (Kakizaki et al., 1999).     
     In the present set of experiments, it was observed that IL-1β caused similar inhibitory 
trends in learning and memory and on hippocampal LTP as LPS, but, alone, was not 
sufficient to induce reliable inhibition.  It follows from this observation that other 
proinflammatory cytokines are required in the periphery to induce cognitive dysfunction.  
It is more than reasonable, then, to suspect tnf-α and / or IL-6 as having a stronger 
peripheral role in sickness-induced cognitive dysfunction than that of IL-1β.  Certainly, 
additional experiments should investigate the effects of peripheral IL-6 and tnf-α on 
learning, memory, and on hippocampal physiology via a drug “cocktail”-like approach. 
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      Second, it is evident from the data, that sickness-induced cognitive dysfunction is not 
reliably produced across tasks by the peripheral administration of LPS.  The strongest 
evidence for a LPS-induced learning and memory impairment (Pugh et al., 1998; 
Experiment 3) support a role for LPS in the disruption of recently acquired 
representations.  Additional experiments should investigate whether this impairment 
generalizes to other tasks.  Though an attempt was made in Experiment 5 to investigate 
whether the LPS-induced impairment observed in Experiment 3 generalized to a 
consolidation version of the Morris Water task, the tasks demands differed.  Using a 
moving-platform version of the MWT, it would be worthwhile to investigate whether 
LPS, when administered immediately after one block of training, would disrupt retention 
for the platform’s location in a different environment than the one in which animals had 
received the training.  A task such as this should reveal whether the LPS-induced 
impairment in memory consolidation (Experiment 3; Pugh et al., 1998) is specific to 
recently-acquired representations across different tasks. 
     In addition, though an inhibitory effect of LPS on the EPSP was observed in 
Experiment 8, this effect was noticeable solely at the 24-hour time point.  It would be 
worthwhile to investigate if this LPS-induced inhibition in EPSP maintenance is the 
result of a direct inhibitory effect of LPS on hippocampal synaptic plasticity, or if it is the 
result of an indirect enhancing effect of LPS on slow-wave sleep, which in turn, inhibits 
hippocampal synaptic plasticity.  Results from the final experiment suggest that 
peripheral cytokines do have direct, inhibitory effects on hippocampal physiology; 
however, additional experiments that investigate the effects of peripheral administration 
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 of LPS on LTP in an animal whose activity state was artificially maintained would 
strengthen this assumption. 
     Certainly, more empirical investigation needs to be done in order to fully understand 
the effects of the peripheral immune response on cognition.  Data from Experiments 1-10 
have characterized the cognitive process that is disrupted during infection and have 
demonstrated a cytokine-specific disruption of two physiological processes within the 
hippocampus linked to learning and memory.  Additionally, the data have shown 
peripheral IL-1β to be virtually ineffective at disrupting cognition across a variety of 
doses and paradigms.  Finally, data from Experiment 10 have provided preliminary 
evidence of additional proinflammatory cytokines acting in the periphery to disrupt 
central learning and memory processes. Additional experiments that are re-directed 
toward answering the questions posed above should provide for a more sound basis on 
which anti-cytokine therapy for sickness and inflammation-induced cognitive dysfunction 
can be discovered. 
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 Appendix A:  LPS and IL-1β Effects on Brain Temperature 
 
 
     In addition to food consumption, weight, and general activity measurement, three 
three-hour measurements of brain temperature were recorded in an animal injected with:  
250 μg/kg of LPS, 25 μg/kg of  IL-1β, or an equivalent volume of pyrogen-free saline.  
The rise and fall of brain temperature has been observed to closely mirror that of core 
body temperature (Sundgren-Andersson, Ostlund, & Bartfai, 1998), and so it can be 
expected that if LPS and / or IL-1β provoke a peripheral immune response, it should be 
evident in a rise in brain temperature.   
 
Implantation 
     Rats were anesthetized  with isoflourane (O2 flow rate 1.5 l/min at 1.5-2% 
isoflourane) for chronic implantation. Rats were implanted, using aseptic surgical 
techniques, with two temperature probes (physitemp, custom 29 ga needle probe, T-
107D). Both probes were aimed at the hilar region of the bilateral dentate gyrus  (Paxinos 
& Watson coordinates: 3.5 mm posterior to the bregma, 2.0 mm lateral to themidline, and 
3.5 mm below the top of the skull). Three stainless-steel,jewelers’ screws tapped into the 
skull provided structural support for the probes, which were held in place by dental 
acrylic cement. The skin incision was closed with veterinary glue and the rats received 
injections of penicillin G (60,000 I.U. subcutaneous(sc)) and buprenorphine (0.05 mg/kg 
i.p.).  The animal was allowed to recover for one week prior to testing. 
 
Temperature Monitoring 
     Brain temperature was recorded on a monitor (Physitemp, thermalert model TH-8 
temperature monitor) while the animal was allowed to freely move around in its cage.  
Temperature was recorded in twenty-second intervals during a one-hour baseline 
recording, and during the two hours following the injection. 
 
Injections 
     The animal was injected with either: 250 μg/kg of LPS ((Ecoli 026:B6); Sigma, Lot 
no. 101K4080; 3 million endotoxin units per MG), 25 μg/kg IL-1β ((RDI) catalog no. 
RDI-201b), or an equivalent volume of pyrogen-free saline (Abbot Laboratories, Lot no. 
79-613-DM-01).  The doses were chosen based on a previous experiment that had 
observed changes in temperature following these doses (Konsman et al., 2000); however, 
doses as low as 2 μg/kg of IL-1β have been observed to induce a febrile response 
(Yirmiya, et al. 1996).  The order of injections was:  saline, LPS, IL-1β.  Each injection 
was spaced one day apart.  Because temperature has previously been observed to return 
to baseline values within eight hours after injection (Yirmiya, et al. 1996), 24 hours 
between testing is more than sufficient to allow any increases in temperature to return to 
baseline values. 
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    Appendix A.  Effects of  250 μg/kg LPS, 25 μg/kg IL-1β, or an equi-volume a mount of pyrogen-free saline on brain      
     temperature,  expressed as the average fractional change (AFC) from baseline.  N = 1. 
 
 
Conclusion 
     Brain temperature began to rise approximately 1 hour and 30 minutes following an 
injection with LPS and IL-1β; whereas, in the saline-treated animal, brain temperature 
began to drop as the animal started to fall asleep (activity state only observed by the 
experimenter, and not video-monitored).   
     Because brain temperature has been observed to closely mirror the temperature of the 
peritoneum (Sundgren-Andersson et al., 1998), it can be concluded that both LPS and IL-
1β induce a febrile response in the rat. 
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 Appendix B:  Verification of Recording Electrode Placement 
 
 
 
 
 
Appendix B.  Coronal section showing trace of the recording elelectrode, aimed at the 
hilar region of the dentate gyrus  (Paxinos & Watson coordinates: 3.5 mm posterior to the 
bregma, 1.8 mm lateral to the midline, and 3.6 mm below the top of the skull) 
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Appendix C:  Dose-Response Curve for LPS and IL-1β Effects on Hippocampal Long-
Term Potentiation (LTP) in the Freely-Moving Rat 
 
     Because no previous experiments have measured the effects of LPS or IL-1β on LTP 
in the freely-moving rat, a dose-response curve was conducted to find the dose(s) at 
which LPS and / or IL-1β would most likely inhibit hippocampal LTP in a larger 
experiment. 
     The implantation method, electrophysiology apparatus, and recording method were all 
identical to that which was described in the Procedure section of Experiments 8 and 9. 
     On testing day, an input-out  (I-O) curve was produced for each animal to determine 
the baseline stimulus intensity.  A pre-injection baseline recording was then taken.  All 
animals were then injected with saline, after which high-frequency stimulation (HFS) was 
delivered. 
Injections 
     Following the first delivery of HFS, animals were injected i.p. with cumulative doses 
of LPS ((Ecoli 026:B6); Sigma, Lot no. 101K4080; 3 million endotoxin units per MG) or 
IL-1β ((RDI) catalog no. RDI-201b).  Cumulative doses ranged from 2 μg/kg to 100 
μg/kg and were spaced approximately one hour apart.  Each delivery of HFS was spaced 
approximately 45 minutes after each injection, and stimulation parameters were returned 
to baseline values after each HFS delivery.  Changes in the evoked responses were 
expressed as fractional changes from the original values measured at the pre-injection 
baseline, as has been previously described. 
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  Appendix C.  Effects of cumulative doses of LPS, IL-1β, and saline on hippocampal LTP in 
  the freely-moving rat.  LTP is expressed as the average fractional change (AFC) in pop-spike 
  amplitude (top) and EPSP slope (bottom).  N=3. 
 
Conclusions 
A dose of 12 μg/kg was chosen for both LPS and IL-1β as the dose most likely to inhibit 
hippocampal LTP.  This dose was chosen because it fell mid-way between the doses 
which appeared to cause the most inhibition in the EPSP (8 μg/kg – 16 μg/kg) and the 
population spike, as evidenced by the downward deflection of the curve at these values. 
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 Appendix D:  Hippocampal Long-Term Potentiation (LTP) in the Freely-Moving Rat:  
Continuous Recording 
 
     To explore the possibility that experimental handling, necessary to the connection of 
the animal to the recording apparatus, confounded the change in the EPSP following HFS 
(Experiments 8,9), the evoked potential following HFS was measured continuously for 
approximately two hours, and then again at 24 hours.  The animal was left unperturbed in 
its cage for the duration of the experiment. 
     The implantation method, electrophysiology apparatus, and recording method were all 
identical to that which was described in the Procedure section of Experiments 8 and 9. 
     On testing day, an input-out  (I-O) curve was produced for the animal to determine the 
baseline stimulus intensity.  A 30-pulse baseline recording was then collected.  Forty-five 
minutes later, high-frequency stimulation (HFS) was delivered.  Parameters were then 
returned to baseline values and remained there for two hours, and again at 24 hours.  
Changes in the evoked responses were expressed as fractional changes from the original 
values measured at the pre-injection baseline. 
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       Appendix D.  LTP expression in freely-moving, unperturbed rat.  LTP is expressed as the average fractional  
    change (AFC) in pop spike amplitude and EPSP slope following tetanus.  N = 1. 
 
 
Conclusions 
     The change in the EPSP over the 2 hour period mirrored that of the majority of 
animals in Experiments 8 and 9.  That is, the initial rise in the AFC of the EPSP 
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following HFS slowly diminished over the course of one hour until it fell below baseline 
values.  It then returned to higher-than-baseline values at 24 hours.  Presumably, then, the 
depressed EPSP that was observed at 75 minutes in saline-treated animals in Experiments 
8 and 9 was not an artifact of experimental handling, but rather was a result of differences 
in the animals’ body core temperatures as a function of activity state.  This is further 
explained in the Conclusions section of Experiments 8 and 9.   
 
 
